https://www.medthority.com/medical-education/atopic-derm/publication-digests/results-from-head-to-head-phase-3-atopic-dermatitis-clinical-trial-of-systemic-treatments/videos/rationale-for-the-jade-dare-study/2026-01-27T16:01:50+00:00weekly0.5https://www.medthority.com/medical-education/atopic-derm/publication-digests/results-from-head-to-head-phase-3-atopic-dermatitis-clinical-trial-of-systemic-treatments/videos/research-methods-used-in-jade-dare/2026-01-27T16:01:44+00:00weekly0.5https://www.medthority.com/medical-education/atopic-derm/publication-digests/results-from-head-to-head-phase-3-atopic-dermatitis-clinical-trial-of-systemic-treatments/videos/primary-outcomes-in-jade-dare/2026-01-27T16:01:38+00:00weekly0.5https://www.medthority.com/medical-education/atopic-derm/publication-digests/results-from-head-to-head-phase-3-atopic-dermatitis-clinical-trial-of-systemic-treatments/videos/implications-of-jade-dare-for-clinical-practice/2026-01-27T16:01:31+00:00weekly0.5https://www.medthority.com/medical-education/atopic-derm/publication-digests/results-from-head-to-head-phase-3-atopic-dermatitis-clinical-trial-of-systemic-treatments/videos/key-factors-in-initiating-jak-inhibitors-for-atopic-dermatitis/2026-01-27T16:01:26+00:00weekly0.5https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/esmo-2025-prostate-cancer-highlights/transcript-esmo-2025-pc-data-highlights/2025-12-15T10:53:57+00:00weekly0.5https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/addressing-disparities-in-hrrm-testing-access/transcript-disparities-in-hrrm-testing-access/2025-12-15T10:54:44+00:00weekly0.5https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/unpacking-nmibc-insights-from-esmo-2025/transcript-unpacking-nmibc-insights-from-esmo-2025/2025-12-12T10:20:29+00:00weekly0.5https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/a-patients-view-on-shaping-nmibc-care/transcript-a-patients-view-on-nmibc-care-pathways/2025-12-12T10:15:49+00:00weekly0.5https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/a-patients-view-on-navigating-nmibc-diagnosis/transcript-a-patient-on-navigating-nmibc-diagnosis/2025-12-12T10:13:46+00:00weekly0.5https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/interpreting-hrr-results-with-confidence/transcript-interpreting-hrr-results-with-confidence/2025-12-15T10:53:03+00:00weekly0.5https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/recurrence-and-support-in-nmibc-care/transcript-alison-birtle-on-patient-fears-in-nmibc/2025-12-12T10:19:05+00:00weekly0.5https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/cystectomy-versus-bladder-sparing-treatments/transcript-cystectomy-vs-bladder-sparing-options/2025-12-12T09:27:34+00:00weekly0.5https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/real-world-therapy-sequencing-in-mpc/transcript-real-world-therapy-sequencing-in-mpc/2025-12-15T15:07:01+00:00weekly0.5https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/future-proofing-hrr-testing-in-mpc/transcript-whats-next-in-hrr-testing/2025-12-15T11:01:36+00:00weekly0.5https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/surveillance-in-intermediate-bladder-cancer/transcript-nmibc-surveillance-and-follow-up/2025-12-12T10:17:59+00:00weekly0.5https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/navigating-nmibc-treatment-changes/transcript-navigating-nmibc-treatment-changes/2025-11-20T11:28:16+00:00weekly0.5https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/how-emerging-therapies-could-change-practice/transcript-the-future-of-nmibc-treatment/2025-12-12T10:16:58+00:00weekly0.5https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/patient-views-genetic-testing-in-mpc/transcript-patient-views-on-genetic-testing-in-mpc/2025-12-15T10:56:11+00:00weekly0.5https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/transcripts/transcript-selecting-the-right-treatment-approach/2025-12-12T10:22:16+00:00weekly0.5https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/transcripts/transcript-smart-risk-tools-to-personalize-nmibc-care/2025-12-12T10:21:43+00:00weekly0.5https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/optimizing-csu-care/videos/expert-insights-csu-treatment-escalation/2026-01-12T14:53:30+00:00weekly0.5https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/optimizing-csu-care/videos/expert-insights-the-future-of-csu-treatment/2026-01-12T14:51:48+00:00weekly0.5https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/optimizing-csu-care/videos/expert-insights-csu-treatment-advances/2026-01-12T14:52:24+00:00weekly0.5https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/optimizing-csu-care/videos/expert-insights-evolving-csu-care/2026-01-12T14:52:56+00:00weekly0.5https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/expert-opinions-on-mcrpc-management/videos/mcrpc-management-unpacked-imaging-genetic-testing-and-treatment-decisions/2026-01-27T15:34:29+00:00weekly0.5https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/expert-opinions-on-mcrpc-management/videos/can-investigational-treatments-address-unmet-needs-in-mcrpc/2026-01-27T15:34:22+00:00weekly0.5https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/expert-opinions-on-mcrpc-management/videos/barriers-to-uptake-of-clinical-practice-guidelines-for-mcrpc/2026-01-27T15:34:15+00:00weekly0.5https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/expert-opinions-on-mcrpc-management/videos/important-considerations-about-patient-populations-in-mcrpc-trials/2026-01-27T15:34:07+00:00weekly0.5https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/expert-opinions-on-mcrpc-management/videos/differences-in-clinical-trial-design-for-parp-inhibitors-and-novel-hormonal-therapies/2026-01-27T15:33:58+00:00weekly0.5https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/transcripts/transcript-diagnosis-which-tools-should-be-used-when/2025-12-12T10:25:53+00:00weekly0.5https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/transcripts/transcript-diagnosis---navigating-multiple-guidelines/2025-12-12T10:25:21+00:00weekly0.5https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/eadv-2024/transcripts/transcript-the-potential-impact-of-targeted-treatments-in-hs/2026-01-14T09:18:20+00:00weekly0.5https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/eadv-2024/transcripts/transcript-standard-of-care-for-hs/2026-01-14T09:17:47+00:00weekly0.5https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/eadv-2024/transcripts/transcript-supporting-patients/2026-01-14T09:16:53+00:00weekly0.5https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/eadv-2024/transcripts/transcript-diagnosing-hidradenitis-suppurativa/2026-01-14T09:15:58+00:00weekly0.5https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/eadv-2024/transcripts/transcript-multidisciplinary-care-and-clinical-barriers/2026-01-14T09:14:45+00:00weekly0.5https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/eadv-2024/transcripts/transcript-investigational-treatments-for-hs/2026-01-14T09:04:30+00:00weekly0.5https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/eadv-2024/transcripts/transcript-european-guideline-updates/2026-01-14T09:00:18+00:00weekly0.5https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/eadv-2024/transcripts/transcript-hs-diagnosis-experience/2026-01-14T08:54:24+00:00weekly0.5https://www.medthority.com/medical-education/ulcerative-colitis/ulcerative-colitis-overview/videos/what-are-key-unmet-needs-and-challenges-in-uc-management-and-how-do-they-impact-clinical-practice/2026-01-27T14:41:27+00:00weekly0.5https://www.medthority.com/medical-education/ulcerative-colitis/ulcerative-colitis-overview/videos/what-are-the-key-unmet-needs-and-challenges-relating-to-the-diagnosis-of-uc-in-practice/2026-01-27T14:41:23+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/lipid-management-at-esc-2023-congress-highlights/esc-2023-videos/the-issue-of-polypharmacy-in-cvd-risk-management/2026-01-15T09:57:45+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/lipid-management-at-esc-2023-congress-highlights/esc-2023-videos/esc-expert-highlights-experts-discuss-key-data-beyond-the-lipid-lowering-trials/2026-01-15T09:56:24+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/lipid-management-at-esc-2023-congress-highlights/esc-2023-videos/esc-2023-expert-highlights-stephen-nicholls-on-a-possible-alternative-for-lowering-lpa/2026-01-15T09:55:19+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/lipid-management-at-esc-2023-congress-highlights/esc-2023-videos/esc-2023-expert-highlights-pam-taub-on-a-novel-approach-to-lpa-reduction/2026-01-15T09:54:06+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/lipid-management-at-esc-2023-congress-highlights/esc-2023-videos/esc-2023-expert-highlights-a-compressed-state-of-the-art-lecture-with-stephen-nicholls/2026-01-15T09:45:34+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/lipid-management-at-esc-2023-congress-highlights/esc-2023-videos/esc-2023-highlights-new-data-and-key-messages/2026-01-15T09:52:50+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/lipid-management-at-esc-2023-congress-highlights/esc-2023-videos/esc-2023-expert-highlights-the-joint-esceas-session-in-4-minutes-with-paul-ridker/2026-01-15T09:51:45+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/lipid-management-at-esc-2023-congress-highlights/esc-2023-videos/esc-2023-expert-highlights-paul-ridker-reviews-the-key-data-on-inflammation/2026-01-15T09:47:29+00:00weekly0.5https://www.medthority.com/medical-education/complement-mediated-kidney-diseases-learning-zone/congress-highlights/videos/what-treatment-strategies-are-currently-being-investigated-for-c3g/2026-01-16T10:24:38+00:00weekly0.5https://www.medthority.com/medical-education/complement-mediated-kidney-diseases-learning-zone/congress-highlights/videos/promising-treatment-targets-for-c3-glomerulopathy-and-other-cmkds/2026-01-16T10:23:53+00:00weekly0.5https://www.medthority.com/medical-education/complement-mediated-kidney-diseases-learning-zone/congress-highlights/videos/the-asn-2022-congress-key-findings-and-their-impact-on-the-management-of-cmkds/2026-01-16T10:22:58+00:00weekly0.5https://www.medthority.com/medical-education/complement-mediated-kidney-diseases-learning-zone/congress-highlights/videos/the-asn-2022-congress-new-data-about-novel-treatments-for-c3-glomerulopathy-and-other-cmkds/2026-01-16T10:22:12+00:00weekly0.5https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/congress-highlights/esmo-2022-videos/key-takeaways-from-esmo-2022/2026-01-27T15:25:52+00:00weekly0.5https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/congress-highlights/esmo-2022-videos/esmo-2022-clinical-trial-data-reveal-the-impact-of-parpis-on-overall-survival-at-different-time-points-in-the-natural-history-of-ovarian-cancer/2026-01-27T15:25:33+00:00weekly0.5https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/congress-highlights/esmo-2022-videos/the-most-impactful-data-presented-at-esmo-2022-and-how-these-may-affect-clinical-practice-and-patient-outcomes/2026-01-27T15:24:59+00:00weekly0.5https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/congress-highlights/esmo-2022-videos/data-supporting-the-use-of-parpis-in-the-first-line-setting/2026-01-27T15:24:10+00:00weekly0.5https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/congress-highlights/esmo-2022-videos/the-impact-of-the-data-on-guideline-indications-for-parpis-in-ovarian-cancer/2026-01-27T15:24:39+00:00weekly0.5https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/congress-highlights/esmo-2022-videos/meet-professor-antonio-gonzalez-martin/2026-01-27T15:23:51+00:00weekly0.5https://www.medthority.com/medical-education/respiratory-syncytial-virus/ers-2022-congress-highlights/ers-2022-videos/meet-professor-francesco-blasi/2026-01-27T15:11:56+00:00weekly0.5https://www.medthority.com/medical-education/respiratory-syncytial-virus/ers-2022-congress-highlights/ers-2022-videos/meet-doctor-ting-shi/2026-01-27T14:45:23+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/congress-highlights/esmo-2022-videos/professor-nadia-harbeck-introduction/2026-01-13T10:00:26+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/congress-highlights/esmo-2022-videos/esmo-breast-cancer-2022-main-takeaways/2026-01-13T09:59:30+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/congress-highlights/esmo-2022-videos/cdk46-inhibitor-new-data-and-clinical-implications/2026-01-13T09:58:44+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/congress-highlights/esmo-2022-videos/cdk46-inhibitor-approvals-in-europe-and-the-us/2026-01-13T09:57:38+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/what-is-emerging-real-world-evidence-for-inclisiran-showing-so-far/2026-01-15T10:57:10+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/what-implications-do-real-world-findings-have-for-clinical-practice/2026-01-15T10:55:51+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/what-developments-in-ldl-c-lowering-sirna-therapy-can-support-healthcare-professionals-and-patients-to-achieve-maintain-and-sustain-ldl-c-reductions/2026-01-15T10:54:26+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/what-are-the-advantages-of-ldl-c-lowering-sirna-therapy-in-clinical-practice/2026-01-15T10:52:48+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/what-is-the-evidence-for-lpa-testing/2026-01-15T10:48:15+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/how-can-lpa-testing-inform-lipid-management-in-people-with-or-at-risk-of-ascvd/2026-01-15T10:46:59+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/why-is-statin-therapy-not-considered-sufficient/2026-01-15T10:45:52+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/how-can-clinicians-work-with-patients-to-achieve-optimal-lipid-lowering-targets/2026-01-15T10:43:54+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/please-describe-key-ldl-c-management-strategies-that-aim-to-achieve-long-term-reduction-of-total-exposure-to-ldl-c/2026-01-15T10:42:46+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/are-e-consultation-programs-an-opportunity-to-improve-management-of-cardiology-patients/2026-01-15T10:35:44+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/key-message-for-cardiologists---professor-oliver-weingartner/2026-01-15T10:34:36+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/key-message-for-cardiologists--professor-stephen-nicholls/2026-01-15T10:33:18+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/common-challenges-of-treating-with-aceiarbs-in-this-population/2026-01-16T09:38:25+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/what-do-you-consider-were-key-discussions-relating-to-ascvd-at-the-esc-2022-congress/2026-01-15T10:31:07+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/esc-2022-most-valuable-insights-for-ascvd/2026-01-15T10:29:50+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/have-there-been-advances-in-the-development-of-lpa-lowering-therapies/2026-01-15T10:28:37+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/are-there-new-or-investigational-therapies-that-target-lpa/2026-01-15T10:27:10+00:00weekly0.5https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/videos/what-are-the-most-important-issues-in-lipid-management-to-reduce-risk-of-ascvd/2026-01-15T10:18:49+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/expert-opinion/cdk46-inhibitors-as-adjuvant-therapy-in-early-breast-cancer-videos/early-breast-cancer-guideline-update/2026-01-13T09:44:05+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/expert-opinion/cdk46-inhibitors-as-adjuvant-therapy-in-early-breast-cancer-videos/cdk-46-inhibitors-for-early-stage-hr-breast-cancer/2026-01-13T09:43:03+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/expert-opinion/cdk46-inhibitors-as-adjuvant-therapy-in-early-breast-cancer-videos/abemaciclib-approval-and-clinical-use-for-hrher2--breast-cancer/2026-01-13T09:42:14+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/expert-opinion/cdk46-inhibitors-as-adjuvant-therapy-in-early-breast-cancer-videos/why-did-the-fda-approve-abemaciclib-for-breast-cancer-based-on-ki-67-data/2026-01-13T09:41:28+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/expert-opinion/cdk46-inhibitors-as-adjuvant-therapy-in-early-breast-cancer-videos/is-there-a-scenario-to-use-a-cdk46-inhibitor-apart-from-abemaciclib-for-breast-cancer/2026-01-13T09:40:31+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/expert-opinion/cdk46-inhibitors-as-adjuvant-therapy-in-early-breast-cancer-videos/understanding-the-pallas-results-data-from-the-penelope-b-and-monarche-clinical-trials/2026-01-13T09:31:30+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/expert-opinion/cdk46-inhibitors-as-adjuvant-therapy-in-early-breast-cancer-videos/diarrhoea-management-and-nutrition-in-early-breast-cancer/2026-01-13T09:30:44+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/duplicates/key-insights-from-ectrims-2022-with-dr-victoria-leavitt2/2026-01-27T11:41:14+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/duplicates/what-were-some-key-highlights-from-ectrims-2022-that-you-consider-important-for-clinical-practice2/2026-01-27T11:40:35+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/duplicates/what-is-the-latest-evidence-on-new-generation-therapies-for-first-line-intervention-in-ms-2/2026-01-27T11:40:12+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/duplicates/in-your-own-practice-how-do-you-approach-treatment-selection-for-people-with-ms-v2/2026-01-27T11:39:51+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/duplicates/what-are-key-considerations-for-pregnancy-and-family-planning-for-patients-with-multiple-sclerosis-v2/2026-01-27T11:39:29+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/duplicates/what-is-the-latest-evidence-on-the-safety-profile-of-anti-cd20-therapies-in-ms-v2/2026-01-27T11:39:05+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/duplicates/how-has-management-of-ms-evolved-since-you-were-diagnosed-v2/2026-01-27T11:38:44+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/duplicates/what-can-healthcare-professionals-do-to-improve-care-for-people-with-multiple-sclerosis-and-improve-management-of-the-disease-v2/2026-01-27T11:38:13+00:00weekly0.5https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/congress-highlights/acr-2022-congress-highlights/what-were-the-key-discussions-happening-at-the-acr-2022-congress/2026-01-19T11:00:07+00:00weekly0.5https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/congress-highlights/acr-2022-congress-highlights/what-were-some-research-highlights-regarding-the-use-of-biosimilars-in-rheumatoid-arthritis-and-related-conditions/2026-01-19T10:58:59+00:00weekly0.5https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/congress-highlights/acr-2022-congress-highlights/were-there-any-non-clinical-developments-to-mention/2026-01-19T10:57:54+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/congress-highlights/asco-2022-videos/what-were-some-of-the-important-discussions-to-emerge-from-the-asco-2022-congress/2026-01-13T10:25:14+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/congress-highlights/asco-2022-videos/cdk46-inhibitors-approved-for-treatment-of-hrher2--early-breast-cancer-and-nuances-in-fda-and-ema-indications/2026-01-13T10:24:07+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/congress-highlights/asco-2022-videos/can-treatment-of-hrher2--early-breast-cancer-be-personalised/2026-01-13T10:23:01+00:00weekly0.5https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/congress-highlights/asco-2022-videos/meet-dr-gregory-vidal/2026-01-13T10:21:56+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/what-are-some-of-the-highlights-from-ckd-research-presented-at-the-era-2022-congress/2026-01-16T09:55:23+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/were-there-any-updates-of-major-ckd-clinical-trials-presented-at-the-era-2022-congress/2026-01-16T09:54:29+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/what-were-the-findings-from-the-reveal-ckd-study-presented-at-the-era-2022-congress/2026-01-16T09:53:38+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/what-is-the-relationship-between-ckd-and-cardiovascular-disease/2026-01-16T09:52:48+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/were-there-any-developments-regarding-the-overlap-between-ckd-and-type-2-diabetes-at-the-era-2022-congress/2026-01-16T09:52:03+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/what-were-some-of-the-research-highlights-regarding-treatment-of-ckd-with-sglt2-inhibitors/2026-01-16T09:51:22+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/what-were-some-of-the-research-highlights-regarding-the-use-of-mras-for-the-treatment-of-ckd/2026-01-16T09:45:47+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/introduction-to-professor-navdeep-tangri/2026-01-16T09:45:02+00:00weekly0.5https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/congress-highlights/asco-2022-videos/what-were-the-most-important-ovarian-cancer-discussions-to-emerge-from-asco-2022/2026-01-27T15:27:56+00:00weekly0.5https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/congress-highlights/asco-2022-videos/what-were-the-most-impactful-data-presented-for-advanced-ovarian-cancer/2026-01-27T15:27:43+00:00weekly0.5https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/congress-highlights/asco-2022-videos/how-will-the-parp-inhibitor-data-impact-clinical-practice-and-patient-outcomes-in-ovarian-cancer-in-the-future/2026-01-27T15:27:30+00:00weekly0.5https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/congress-highlights/asco-2022-videos/meet-the-expert/2026-01-27T15:27:15+00:00weekly0.5https://www.medthority.com/medical-education/lupus-learning-zone/congress-highlights/eular-2022-videos/what-important-topics-relating-to-lupus-management-emerged-from-the-eular-2022-congress/2025-12-15T09:36:22+00:00weekly0.5https://www.medthority.com/medical-education/lupus-learning-zone/congress-highlights/eular-2022-videos/late-breaking-abstracts-on-lupus-management-presented-at-the-eular-2022-congress/2025-12-15T09:35:54+00:00weekly0.5https://www.medthority.com/medical-education/lupus-learning-zone/congress-highlights/eular-2022-videos/what-new-treatments-have-been-approved-recently-for-lupus-nephritis/2025-12-15T09:35:29+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/what-was-the-rationale-of-the-dapa-ckd-post-hoc-analysis-presented-at-the-era-2022-congress/2026-01-16T09:44:03+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/what-were-the-key-results-of-the-dapa-ckd-post-hoc-analysis-and-the-clinical-implications-for-managing-ckd-progression/2026-01-16T09:43:08+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/is-dapagliflozin-effective-for-preventing-ckd-progression-and-cardiovascular-outcomes-in-patients-not-taking-an-ace-inhibitor-or-arb/2026-01-16T09:42:21+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/what-was-the-aim-of-your-study-investigating-the-correlates-of-sglt2-inhibitors-on-egfr-response/2026-01-16T09:41:23+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/what-were-the-main-findings-of-your-study-investigating-the-correlates-of-sglt2-inhibitors-on-egfr-response/2026-02-02T15:41:42+00:00weekly0.5https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/era-2022-videos/introduction-to-professor-hiddo-heerspink/2026-01-16T09:39:27+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/how-do-acute-lesions-evolve-into-chronic-lesions-in-multiple-sclerosis/2026-01-27T13:59:49+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/are-patients-equally-affected-by-changes-in-multiple-sclerosis-pathology-over-time/2026-01-27T13:59:27+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/is-it-possible-to-profile-multiple-sclerosis-patients-in-vivo/2026-01-27T13:59:04+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/is-there-evidence-that-current-drug-treatments-target-multiple-sclerosis-pathologies/2026-01-27T13:58:41+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/do-drug-treatments-for-multiple-sclerosis-improve-long-term-clinical-outcomes/2026-01-27T13:58:13+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/should-high-efficacy-therapies-be-initiated-only-for-advanced-multiple-sclerosis-or-in-older-adults/2026-01-27T13:57:38+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/what-is-the-target-of-high-efficacy-therapies-for-multiple-sclerosis/2026-01-27T13:57:20+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/what-do-we-understand-about-vaccines-for-people-with-ms-in-the-covid-19-era/2026-01-27T13:56:54+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/should-high-efficacy-therapies-be-first-line-treatment-for-every-patient-with-multiple-sclerosis/2026-01-27T13:56:21+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/what-will-the-future-treatment-landscape-of-multiple-sclerosis-look-like/2026-01-27T13:55:55+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/how-significant-is-the-burden-of-multiple-sclerosis/2026-01-27T13:55:20+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/are-high-efficacy-treatments-effective-for-multiple-sclerosis/2026-01-27T13:54:35+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/from-the-individual-to-society-what-does-the-new-evidence-show-about-the-burden-of-multiple-sclerosis/2026-01-27T13:54:18+00:00weekly0.5https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/expert-opinion/ectrims-2021/what-are-the-barriers-to-prescribing-high-efficacy-therapies-for-multiple-sclerosis/2026-01-27T13:53:28+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-kristin-highland/fibrosis-begets-fibrosis/2026-01-27T15:55:29+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-elisabeth-bendstrup/important-for-physicians-to-know-about-ipf/2026-01-27T15:57:40+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-elisabeth-bendstrup/drugs-targeting-biologically-plausible-mechanisms/2026-01-27T15:58:01+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-elisabeth-bendstrup/gp-or-non-specialist/2026-01-27T15:57:55+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-mrowietz-pasi-100-an-outcome-too-far/2025-12-09T15:33:23+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-mrowietz-managing-comorbidities/2025-12-09T15:32:12+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/biographies/professor-ulrich-mrowietz-meet-the-expert/2025-12-09T15:44:59+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/biographies/professor-rolland-gyulai/2025-12-09T15:44:03+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/eadv-2018-insights/primary-treatment-goal-of-psoriasis/2025-12-09T15:41:48+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/eadv-2018-insights/comorbidities-impact-patients-with-psoriasis/2025-12-09T15:37:24+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/eadv-2018-insights/how-does-psoriasis-affect-patients-quality-of-life/2025-12-09T15:37:58+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-elisabeth-bendstrup/highlights-of-the-ers-congress-2019/2026-01-27T15:57:45+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-elisabeth-bendstrup/identification-of-genetic-polymorphisms/2026-01-27T15:55:42+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-kristin-highland/screening-lung-disease-people-autoimmune-diseases/2026-01-27T15:50:09+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-kristin-highland/anecdotes-of-accurate-diagnosis/2026-01-27T15:50:02+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-kristin-highland/personally-enjoy-working-in-this-specialty/2026-01-27T15:51:34+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-blauvelt-age-and-psoriatic-arthritis/2025-12-09T15:07:21+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-blauvelt-treatment-for-psoriasis/2025-12-09T15:28:46+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-blauvelt-challenges-biologics/2025-12-09T15:04:13+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-mrowietz-patients-attitudes-to-biologics/2025-12-09T15:34:02+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/eadv-2018-insights/what-is-the-prevalence-rate-of-psoriasis/2025-12-09T15:40:26+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-blauvelt-switching-treatment/2025-12-09T15:28:14+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-blauvelt-onset-of-action/2025-12-09T15:26:49+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-blauvelt-selecting-treatment-principles/2025-12-09T15:27:29+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/biographies/professor-andrew-blauvelt-meet-the-expert/2025-12-09T15:42:24+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-mrowietz-non-biological-treatments/2025-12-09T15:35:08+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-mrowietz-psoriasis-as-a-systemic-disease/2025-12-09T15:34:34+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/biographies/professor-paolo-gisondi/2025-12-09T15:43:21+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/eadv-2018-insights/biosimilars-in-the-management-of-psoriasis/2025-12-09T15:41:00+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/eadv-2018-insights/guidelines-and-treatment-armamentarium-changed/2025-12-09T15:38:39+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/eadv-2018-insights/treatment-longevity-choosing-a-therapeutic-option/2025-12-09T15:39:20+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-elisabeth-bendstrup/example-of-anti-fibrotic-treatment/2026-01-27T15:55:58+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-elisabeth-bendstrup/ipf-as-a-fascinating-disease/2026-01-27T15:58:09+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-blauvelt-important-recent-advances/2025-12-09T15:05:47+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-blauvelt-comparing-il17-and-il23/2025-12-09T15:04:48+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-blauvelt-unmet-need/2025-12-09T15:29:21+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-mrowietz-eadv-highlights/2025-12-09T15:30:00+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-mrowietz-treatment-challenges/2025-07-21T12:42:24+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/psoriasis-learning-zone/professor-mrowietz-unmet-need/2025-12-09T15:36:41+00:00weekly0.5https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/eadv-2018-insights/urgent-unmet-needs-among-patients-with-psoriasis/2025-12-09T15:39:56+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-elisabeth-bendstrup/poor-understanding-of-the-disease/2026-01-27T15:56:11+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-kristin-highland/ild-important-to-know/2026-01-27T15:50:15+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-kristin-highland/clinical-features-adverse-events-from-ild/2026-01-27T15:49:47+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-kristin-highland/diagnostic-or-screening-need-in-autoimmune-ild/2026-01-27T15:51:28+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-kristin-highland/results-histopathology-management-autoimmune-ild/2026-01-27T15:49:54+00:00weekly0.5https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-kristin-highland/patients-develop-ild-in-some-subtypes-of-ctd/2026-01-27T15:49:39+00:00weekly0.5https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/videos/platiparp/2026-02-18T11:20:02+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/videos/parpi-inhibitors-in-focus-brcaway_and_talapro-2/2026-03-06T12:28:09+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/videos/olaparib-for-mcrpcp-rwos/2026-02-18T11:21:42+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-removing-tbi-from-ptcl-conditioning/2026-03-12T12:53:51+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-is-r-chop-suitable-for-late-relapse-dlbcl/2026-03-12T12:53:26+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-using-pet-to-guide-chl-treatment-de-escalation/2026-03-12T12:53:02+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-inmind-potential-new-standard-of-care-for-rr-fl/2026-03-12T12:52:38+00:00weekly0.6https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transcripts/transcript-myasthenia-gravis-postpartum-case-study/2025-12-11T10:21:21+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-ebac-accredited-lymphoma-roundtable/2026-03-12T12:54:20+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-the-implications-of-new-treatments-for-patients/2025-12-16T14:55:58+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-what-are-the-biggest-unknowns-in-hs-pathophysiology/2025-12-16T14:56:45+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-what-was-the-most-important-piece-of-new-research-presented-at-eadv-2024/2025-12-16T14:57:12+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-what-are-your-thoughts-on-the-key-findings-for-izokibep/2025-12-16T14:57:38+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-cardiometabolic-risk-in-people-with-hs/2025-12-16T14:58:05+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-cells-mediators-and-bacteria-ehsf-2024-pathophysiology-update2/2025-12-16T15:02:07+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-be-heard-i-and-ii/2025-12-16T15:00:52+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-most-important-issue/2025-12-16T15:00:27+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-new-guidelines/2025-12-16T15:00:02+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-hs-diagnostic-journey/2025-12-16T14:58:31+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-pain-and-quality-of-life/2025-12-16T14:55:23+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/ebac-accredited-lymphoma-roundtable/ebac-quiz-page/2025-12-18T09:16:13+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/ebac-accredited-lymphoma-roundtable/ebac-evaluation/2026-01-27T12:16:27+00:00weekly0.6https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transcripts/transcript-implementing-recent-gmg-guidelines/2025-12-11T10:22:39+00:00weekly0.6https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transcripts/transcript-optimising-gmg-patient-assessment/2025-12-11T10:22:21+00:00weekly0.6https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transcripts/transcript-dr-elena-cortes-vicente/2025-12-11T10:22:02+00:00weekly0.6https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transcripts/transcript-efgartigimod-in-clinical-practice/2025-12-11T10:21:41+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-contact-02-cabozantinib-with-atezolizumab-for-mcrpc/2025-12-11T14:33:50+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-peace-3/2025-12-11T14:31:49+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-radioligand-therapy-for-patients-with-mcrpc/2025-12-11T14:22:59+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript--effectiveness-of-immune-checkpoint-blockade/2025-12-11T14:22:25+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-advances-in-mcrpc-therapy/2025-12-11T14:21:46+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-key-lymphoma-takeaways-from-esmo-2024/2026-03-12T12:56:06+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-high-impact-data-at-esmo-2024/2026-03-12T12:55:40+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-safety-strategies-in-car-t-cell/2026-03-12T12:55:13+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-emerging-lymphoma-therapies-at-esmo-2024/2026-03-12T12:54:47+00:00weekly0.6https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/esc-2023-highlights-article-1/transcript-clinical-features-of-al-amyloidosis/2026-02-09T10:02:37+00:00weekly0.6https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/esc-2023-highlights-article-1/transcript-multidisciplinary-care-for-al-amyloidosis/2026-02-09T10:02:21+00:00weekly0.6https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/esc-2023-highlights-article-1/transcript-diagnostic-advances-for-al-amyloidosis/2026-02-09T10:02:06+00:00weekly0.6https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/esc-2023-highlights-article-2/transcript-data-on-emerging-therapies/2026-02-09T10:04:54+00:00weekly0.6https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/esc-2023-highlights-article-2/transcript-al-amyloidosis-management/2026-02-09T10:03:12+00:00weekly0.6https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/isa-2022-highlights-article-1/transcript-highlights-from-isa-2022/2026-02-09T10:06:50+00:00weekly0.6https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/isa-2022-highlights-article-1/transcript-validated-diagnostic-and-screening-tools/2026-02-09T10:06:35+00:00weekly0.6https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/isa-2022-highlights-article-1/transcript-advice-for-cardiologists/2026-02-09T10:06:21+00:00weekly0.6https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/isa-2022-highlights-article-1/transcript-investigational-treatments/2026-02-09T10:06:04+00:00weekly0.6https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/isa-2022-highlights-article-1/transcript-introduction-to-professor-giovanni-palladini/2026-02-09T10:05:30+00:00weekly0.6https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/isa-2022-highlights-article-3/transcript-approved-treatments-for-al-amyloidosis/2026-02-09T10:07:37+00:00weekly0.6https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/isa-2022-highlights-article-3/transcript-unmet-patient-and-medical-needs/2026-02-09T10:08:02+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-arv-766-a-protac-ar-degrader-for-mcrpc/2025-12-11T14:40:43+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-cyclone-2-reveals-subgroup-benefits/2025-12-11T14:40:06+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-psma-4-can-improve-quality-of-life/2025-12-11T14:37:21+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-benefits-of-precision-medicine-for-mcrpc/2025-12-11T14:36:14+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-chaarted-2-and-a-dream/2025-12-11T14:35:40+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-phase-1-trial-of-mevrometostat-for-crpc/2025-12-11T14:35:02+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-jnj-6420-shows-potential-for-mcrpc/2025-12-11T14:34:26+00:00weekly0.6https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transcripts/transcript-complex-comorbidities/2025-12-11T10:22:57+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-current-and-emerging-therapies/2025-09-01T07:14:11+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-non-hormonal-therapies/2025-09-01T07:13:55+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-key-takeaways-from-eha2024/2026-03-12T12:57:36+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-molecularly-targeted-therapies-key-data-and-future-directions-from-asco-and-eha2024/2026-03-12T12:57:15+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-menopause-missing-links/2026-01-05T08:38:20+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-menopause-unmet-needs/2026-01-05T08:38:12+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-echelon-3-key-findings-and-implications-from-asco-2024/2026-03-12T12:56:51+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-congress-themes-and-overlooked-data/2026-03-12T12:56:27+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-echelon-3-safety-and-dosing-schedule/2026-03-12T12:57:59+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-menopause-and-vms-awareness-and-perspective/2026-01-05T08:38:30+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-oestradiol-withdrawal-and-vms/2025-09-01T07:12:51+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-individual-differences-in-vms/2026-01-05T08:37:46+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-linking-oestradiol-decline-and-depression/2025-09-01T07:11:42+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-oestradiol-and-progesterone-treatments-for-vms/2025-09-01T07:11:25+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-pathophysiology-of-vms/2026-01-05T08:37:20+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-how-basic-science-benefits-vms-management/2026-01-05T08:37:36+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts-roundtable/transcript-platiparp/2025-12-11T14:49:35+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts-roundtable/transcript-parpi-in-focus-brcaway-and-talapro-2/2025-12-11T14:48:55+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts-roundtable/transcript-olaparib-for-mcrpc-rwos/2025-12-11T14:48:08+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts-roundtable/transcript-arv-766-initial-results/2025-12-11T14:47:24+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts-roundtable/transcript-jnj-6420-for-mcrpc-initial-results/2025-12-11T14:46:40+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts-roundtable/transcript-psmafore-hrqol-and-pain/2025-12-11T14:44:25+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts-roundtable/transcript-cyclone-2/2025-12-11T14:43:34+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts-roundtable/transcript-contact-02/2025-12-11T14:42:52+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts-roundtable/transcript-contact-022/2025-12-11T14:42:14+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts-roundtable/transcript-full-mcrpc-roundtable-discussion/2025-12-11T14:41:41+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcript/transcript-the-continuing-need-for-improved-mcrpc-treatments/2025-12-11T14:59:10+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcript/transcript-has-management-of-mcrpc-improved-over-time/2025-12-11T14:58:43+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcript/transcript-the-evolving-treatment-landscape-for-mcrpc/2025-12-11T14:58:08+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcript/transcript-what-are-the-unmet-medical-needs-for-management-of-mcrpc/2025-12-11T14:57:43+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcript/transcript-treatment-strategies-that-can-address-unmet-needs-for-mcrpc/2025-12-11T14:57:17+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcript/transcript-esmo-and-nccn-guideline-recommendations-for-mcrpc/2025-12-11T14:56:54+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcript/transcript-esmo-and-nccn-guideline-recommendations-for-mcrpc2/2025-12-11T14:56:34+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcript/transcript-what-guideline-recommendations-are-challenging-to-apply-in-clinical-practice/2025-12-11T14:55:39+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcript/transcript-can-knowledge-of-treatment-mechanism-of-action-improve-mcrpc-management/2025-12-11T14:54:17+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcript/transcript-can-investigational-treatments-address-unmet-needs-in-mcrpc/2025-12-11T14:53:27+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcript/transcript-barriers-to-uptake-of-clinical-practice-guidelines-for-mcrpc/2025-12-11T14:52:46+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcript/transcript-important-considerations-about-patient-populations-in-mcrpc-trials/2025-12-11T14:51:31+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcript/transcript-differences-in-clinical-trial-design-for-parp-inhibitors-and-novel-hormonal-therapies/2025-12-11T14:50:27+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-concomitant-chronic-inducible-urticaria/2026-01-23T10:25:30+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-csu-and-autoimmune-comorbidities/2026-01-23T10:25:01+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-the-role-of-comorbidities-in-csu/2026-01-23T10:24:35+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-delays-in-providing-treatment-for-csu/2026-01-23T10:24:09+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-predicting-urticaria-duration/2026-01-23T10:23:37+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-omalizumab-in-csu-and-concomitant-asthma/2026-01-23T10:23:08+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-emerging-therapies-for-csu-management/2026-01-23T10:22:00+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/congress-highlights/transcript-eau25-hrr-in-mcrpc-expert-takeaways/2025-12-15T10:16:01+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/transcripts/transcript-eau25-expert-reflection/2025-12-12T11:11:11+00:00weekly0.6https://www.medthority.com/medical-education/alopecia/transcripts/transcript-hairs-cultural-impact-and-redefining-beauty/2025-07-23T14:28:52+00:00weekly0.6https://www.medthority.com/medical-education/alopecia/transcripts/transcript-the-huge-psychosocial-impact-of-aa/2025-07-23T14:28:34+00:00weekly0.6https://www.medthority.com/medical-education/alopecia/transcripts/transcript-the-significance-of-a-support-system/2025-07-23T14:14:42+00:00weekly0.6https://www.medthority.com/medical-education/alopecia/transcripts/transcript-ease-the-psychosocial-burden-of-aa/2025-07-23T14:07:53+00:00weekly0.6https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transcripts/transcript-a-case-of-mg-in-a-child/2025-12-11T10:21:01+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/transcripts/transcript-neal-shore-on-bcg-maintenance-for-nmibc/2025-12-12T11:13:08+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/transcripts/transcript-neal-shore-on-nadofaragene-firadenovec/2025-12-12T11:12:41+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/transcripts/transcript-neal-shore-on-icis-and-chemo-in-nmibc/2025-12-12T11:12:13+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/transcripts/transcript-neal-shore-on-ugn-102-for-nmibc/2025-12-12T11:11:43+00:00weekly0.6https://www.medthority.com/medical-education/alopecia/transcripts/transcript-yolanda-lenzy-on-aa-treatments/2025-07-23T14:30:05+00:00weekly0.6https://www.medthority.com/medical-education/alopecia/transcripts/transcript-nikki-vontaya-on-alopecia-treatments/2025-07-23T14:29:06+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/congress-highlights/transcript-talapro-2-at-asco-gu-2025/2025-12-15T10:16:29+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-oligometastatic-disease-at-asco-gu-2025/2025-12-11T14:21:14+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-ctdna-and-psmafore-at-asco-gu-2025/2025-12-11T14:20:42+00:00weekly0.6https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/transcripts/transcript-mcrpc-treatment-landscape/2025-12-11T14:20:05+00:00weekly0.6https://www.medthority.com/medical-education/alopecia/transcripts/transcript-nikki-vontaya-on-alopecia-areata/2025-07-23T14:33:53+00:00weekly0.6https://www.medthority.com/medical-education/alopecia/transcripts/transcript-raising-aa-awareness-in-soc/2025-07-23T14:31:47+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/ebac-accredited-lymphoma-roundtable/leading-lymphoma-expert-insights-roundtable/2026-01-27T12:16:06+00:00weekly0.6https://www.medthority.com/medical-education/alopecia/transcripts/transcript-the-key-reason-for-delayed-aa-diagnosis-in-soc-patients/2025-07-23T14:34:17+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/progress-in-hrr-testing-for-prostate-cancer/quiz/2026-01-27T16:00:33+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/advances-in-diagnosis-and-management/quiz/2026-01-27T15:47:38+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/congress-highlights/transcript-gerhardt-attard-on-amplitude/2025-12-15T10:14:50+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/alopecia-areata-management-update/transcript-alopecia-areata-a-patients-perspective/2025-12-18T10:25:07+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/congress-highlights/transcript-stefanie-zschabitz-on-talapro-2/2025-12-15T10:15:21+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/transcripts/transcript-thomas-powles-on-crest/2025-12-12T11:09:46+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/transcripts/transcript-gary-steinberg-on-cretostimogene-trials/2025-12-12T11:09:16+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-csu-symposium-at-eadv-2023/2026-01-23T10:26:26+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-csu-symposium-at-eaaci-2023/2026-01-23T10:25:58+00:00weekly0.6https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/accredited-aatd-liver-care-journey/accreditation/2026-01-27T16:12:28+00:00weekly0.6https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/accredited-aatd-liver-care-journey/transcript-liver-disease-in-attd-symposium/2025-12-18T14:57:21+00:00weekly0.6https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/why-early-aatd-diagnosis-is-key-to-optimal-liver-disease-management/assessment/2026-01-27T12:13:16+00:00weekly0.6https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/why-early-aatd-diagnosis-is-key-to-optimal-liver-disease-management/what-potential-does-rnai-hold/2026-01-27T12:13:30+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/transcripts/transcript-expert-perspective-bond-003-at-aua-2025/2025-12-12T11:10:38+00:00weekly0.6https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/why-early-aatd-diagnosis-is-key-to-optimal-liver-disease-management/podcast-4/2026-01-27T12:12:48+00:00weekly0.6https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/why-early-aatd-diagnosis-is-key-to-optimal-liver-disease-management/podcast-3/2026-01-27T12:12:58+00:00weekly0.6https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/why-early-aatd-diagnosis-is-key-to-optimal-liver-disease-management/podcast-2/2026-01-27T12:13:06+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-the-cruse-app-for-csu-management/2026-01-23T10:21:30+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-csu-with-isolated-angioedema/2026-01-12T14:58:31+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-management-of-csu-with-antihistamines/2026-01-12T14:58:09+00:00weekly0.6https://www.medthority.com/medical-education/cidp-learning-zone/cidp-demystified-from-diagnosis-to-management/symptoms-that-support-the-diagnosis-of-cidp/2025-12-16T16:08:07+00:00weekly0.6https://www.medthority.com/medical-education/cidp-learning-zone/cidp-demystified-from-diagnosis-to-management/clinical-features-that-differentiate-cidp/2025-12-16T16:07:46+00:00weekly0.6https://www.medthority.com/medical-education/cidp-learning-zone/cidp-demystified-from-diagnosis-to-management/transcript-interview-with-eduardo-nobile-orazio/2025-12-16T15:59:54+00:00weekly0.6https://www.medthority.com/medical-education/cidp-learning-zone/cidp-demystified-from-diagnosis-to-management/transcript-technologies-for-the-diagnosis-of-cidp/2025-12-16T16:00:57+00:00weekly0.6https://www.medthority.com/medical-education/cidp-learning-zone/cidp-demystified-from-diagnosis-to-management/the-importance-of-early-diagnosis-of-cidp/2025-12-16T15:59:17+00:00weekly0.6https://www.medthority.com/medical-education/cidp-learning-zone/cidp-demystified-from-diagnosis-to-management/long-term-complications-associated-with-cidp/2025-12-16T16:08:25+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/alopecia-areata-management-update/transcript-alopecia-areata-diagnostics/2025-12-18T10:24:43+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/understanding-alopecia-areata/transcript-the-value-of-hair/2025-12-18T10:58:13+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/understanding-alopecia-areata/patient-burden-and-the-unmet-needs-in-treatment-and-management/2025-12-18T10:58:45+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/understanding-alopecia-areata/transcript-addressing-unmet-needs-in-aa/2025-12-18T10:57:12+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/understanding-alopecia-areata/transcript-unmet-needs-in-aa-treatment/2025-12-18T10:56:08+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/diagnosis-which-tools-should-be-used-when/2025-12-12T09:28:07+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/diagnosis-making-sense-of-multiple-guidelines/2025-12-12T09:28:31+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/transcripts/transcript-cisto-surprising-lessons-for-patients-and-providers/2025-12-12T11:08:45+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-vicky-mai-on-predictors/2025-12-19T09:51:12+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-gulseren-tuncay-on-remix-studies/2026-01-12T14:57:43+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-gulseren-tuncay-on-the-rifa-cu-study/2026-01-12T14:57:18+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-gulseren-tuncay-on-bridge-study/2026-01-12T14:56:53+00:00weekly0.6https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/transcripts/transcript-gulseren-tuncay-on-csu-phenotype-studies/2026-01-12T14:56:21+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-tzu-fei-wang-on-wave/2025-12-19T09:50:22+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-lana-castellucci-on-cobrra/2026-01-27T16:08:03+00:00weekly0.6https://www.medthority.com/medical-education/ifn-gamma-in-hyperinflammation/secondary-hlhmas-masterclass/evaluation/2025-12-18T16:00:42+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/smart-risk-tools-to-personalize-nmibc-care/2025-12-12T09:29:10+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/brca-mapping-the-mcrpc-genetic-landscape/2025-12-15T10:50:46+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/transcript-navigating-the-genetic-landscape-of-mcrpc/2025-12-15T10:51:16+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/esc-2025-advances-in-understanding/transcript-amalfi-remote-screening-for-af/2025-12-19T09:42:18+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/esc-2025-advances-in-understanding/transcript-hi-pro-anticoagulation-after-provoked-vte/2025-12-19T09:40:47+00:00weekly0.6https://www.medthority.com/medical-education/ifn-gamma-in-hyperinflammation/secondary-hlhmas-masterclass/transcript-secondary-hlhmas-masterclass/2025-12-18T15:59:39+00:00weekly0.6https://www.medthority.com/medical-education/ifn-gamma-in-hyperinflammation/secondary-hlhmas-masterclass/assessment/2025-12-18T16:00:15+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/first-line-treatment-a-patient-tailored-path/2025-11-21T10:43:48+00:00weekly0.6https://www.medthority.com/medical-education/cidp-learning-zone/cidp-demystified-from-diagnosis-to-management/determining-appropriate-initial-treatment-in-cidp/2025-12-16T16:06:28+00:00weekly0.6https://www.medthority.com/medical-education/cidp-learning-zone/cidp-demystified-from-diagnosis-to-management/patients-preferences-in-cidp-treatment-plans/2025-12-16T16:05:43+00:00weekly0.6https://www.medthority.com/medical-education/cidp-learning-zone/cidp-demystified-from-diagnosis-to-management/non-pharmaceutical-disease-management-for-cidp/2025-12-16T16:04:06+00:00weekly0.6https://www.medthority.com/medical-education/cidp-learning-zone/cidp-demystified-from-diagnosis-to-management/current-treatment-options-for-cidp/2025-12-16T16:03:04+00:00weekly0.6https://www.medthority.com/medical-education/cidp-learning-zone/cidp-demystified-from-diagnosis-to-management/emerging-therapies-and-research-areas-in-cidp/2025-12-16T16:01:33+00:00weekly0.6https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transcripts/transcript-a-case-of-myasthenic-crisis/2025-12-11T10:20:04+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/patient-views-genetic-testing-in-mpc/2025-12-15T10:55:44+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/congress-highlights-nmibc/transcript-alban-trial-and-insights-from-esmo-2025/2025-12-12T10:33:10+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/congress-highlights-nmibc/transcript-nmibc-trends-and-research-at-esmo-2025/2025-12-12T10:32:49+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/interpreting-hrr-results-with-confidence/2025-12-15T10:52:34+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/liquid-vs-tissue-biopsy-hrr-testing-choices/2025-12-15T10:51:42+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/transcript-liquid-vs-tissue-biopsy-and-hrr-testing/2025-12-15T10:52:06+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/navigating-nmibc-treatment-changes/2025-10-23T10:41:20+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/unlocking-hrr-testing-why-it-matters-in-mpc/2025-12-15T10:20:02+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/how-emerging-therapies-could-change-practice/2025-12-12T10:16:39+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/transcript-unlocking-the-hrr-pathway/2025-12-15T10:20:27+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/overcoming-barriers-to-hrr-testing/transcript-tackling-barriers-to-hrr-testing/2025-12-15T10:17:40+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/future-proofing-hrr-testing-in-mpc/2025-12-15T10:56:37+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/surveillance-in-intermediate-bladder-cancer/2025-12-12T10:17:21+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/transcripts/transcript-the-future-of-nmibc-trials/2025-12-12T11:07:45+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/transcripts/transcript-regional-differences-in-nmibc/2025-12-12T11:07:17+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/whats-new-in-hrr-testing/2025-12-15T10:34:16+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/transcript-whats-new-in-hrr-testing/2025-12-15T10:50:13+00:00weekly0.6https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/expert-insights-into-aatd/transcript-genetic-testing-in-aatd-related-liver-disease/2026-01-13T09:51:36+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/roundtable-insights-from-2025/transcript-think-thrombosis-insight-from-2025/2025-12-19T09:31:36+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/real-world-therapy-sequencing-in-mpc/2025-12-15T14:38:31+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/addressing-disparities-in-hrrm-testing-access/2025-12-15T10:54:22+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/recurrence-and-support-in-nmibc-care/2025-12-12T10:18:36+00:00weekly0.6https://www.medthority.com/medical-education/esmo-congress-2025/keynote-905-a-practice-changing-trial/transcript-neal-shore-on-keynote-905/2025-11-26T13:48:15+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/congress-highlights-nmibc/transcript-neal-shore-on-the-potomac-trial/2025-12-12T10:26:53+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/congress-highlights-nmibc/transcript-bladderpath-trial-at-esmo-2025/2025-12-12T10:32:27+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/a-patients-view-on-navigating-nmibc-diagnosis/2025-12-12T10:03:37+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/a-patients-view-on-shaping-nmibc-care/2025-12-12T10:14:48+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/unpacking-nmibc-insights-from-esmo-2025/2025-12-12T10:19:42+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/cystectomy-versus-bladder-sparing-treatments/2025-12-12T09:27:11+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/congress-highlights/transcript-nick-james-on-key-pc-insights-from-esmo-2025/2025-12-15T10:14:21+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/esmo-2025-prostate-cancer-highlights/2025-12-15T10:53:31+00:00weekly0.6https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/expert-insights-into-aatd/transcript-the-role-of-primary-care-in-aatd/2026-01-13T14:34:12+00:00weekly0.6https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/expert-insights-into-aatd/transcript-the-evolving-landscape-of-aatd-treatment/2026-03-02T12:13:33+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/overcoming-barriers-to-hrr-testing/equitable-hrr-testing-in-mpc-care/2026-02-18T11:33:47+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/overcoming-barriers-to-hrr-testing/hrr-testing-best-practicesamplecollection/2026-02-18T11:36:50+00:00weekly0.6https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/expert-insights-into-aatd/transcript-pulmonologist-perspectives-on-lung-health-in-aatd/2026-03-02T13:25:16+00:00weekly0.6https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/overcoming-barriers-to-hrr-testing/transcript-best-practices-in-collection-and-preservation/2026-02-16T11:37:42+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/the-most-important-unmet-needs-in-chronic-kidney-disease/2026-01-23T10:16:49+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/why-is-early-diagnosis-of-chronic-kidney-disease-important/2026-01-23T10:16:00+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/screening-for-chronic-kidney-disease-and-common-comorbidities/2026-01-23T10:15:09+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/chronic-kidney-disease-treatment-goals-and-treatment/2026-01-23T10:12:46+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/what-is-the-evidence-behind-more-recently-approved-treatments-for-ckd-with-and-without-diabetes/2026-01-23T10:09:08+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/meet-professor-hiddo-heerspink-and-hear-about-his-expertise-in-chronic-kidney-disease/2026-01-23T10:07:44+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/publication-digest/imaging-in-nsclc-with-ret-rearrangements/2026-01-27T09:27:17+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/acr-2021-highlights/meet-professor-vincent/2026-01-27T15:47:26+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/acr-2021-highlights/the-most-urgent-unmet-needs-in-the-treatment-of-osteoarthritis/2026-01-27T15:47:19+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/acr-2021-highlights/insights-from-osteoarthritis-epidemiology-and-genome-wide-association-studies/2026-01-27T15:47:12+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/acr-2021-highlights/growth-factors-and-other-potential-targets-of-osteoarthritis-treatment-research/2026-01-27T15:47:04+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/acr-2021-highlights/what-are-the-important-elements-of-a-multidisciplinary-approach-to-osteoarthritis-management/2026-01-27T15:45:09+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/acr-2021-highlights/the-most-important-results-from-the-2021-american-college-of-rheumatology-annual-meeting/2026-01-27T15:43:43+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/publication-digest/driver-genes-as-predictive-indicators-of-brain-metastasis-in-advanced-nsclc/2026-01-27T09:26:56+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/publication-digest/canagliflozin-and-renal-outcomes-in-type-2-diabetes-and-nephropathy/2026-01-16T10:10:58+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/publication-digest/effect-of-finerenone-on-chronic-kidney-disease-outcomes-in-type-2-diabetes/2026-01-16T10:11:36+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/publication-digest/identification-of-ntrk-and-ret-fusion-positive-thyroid-cancers/2026-01-27T09:25:46+00:00weekly0.6https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/videos/can-we-achieve-individualisation-of-antiplatelet-treatment-for-nste/2026-01-27T12:10:11+00:00weekly0.6https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/videos/how-can-we-stratify-high-bleeding-risk-and-high-ischaemic-risk/2026-01-27T12:09:48+00:00weekly0.6https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/videos/do-we-have-good-data-for-a-short-dapt-duration-in-patients-at-high-ischaemic-risk/2026-01-27T12:09:17+00:00weekly0.6https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/videos/strategies-for-reducing-bleeding-risk/2026-01-27T12:08:28+00:00weekly0.6https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/videos/antithrombotic-therapy-in-people-with-nste-acs-who-require-long-term-treatment-whats-new/2026-01-27T12:08:03+00:00weekly0.6https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/videos/what-are-possible-combinations-for-triple-antithrombotic-therapy/2026-01-27T12:07:40+00:00weekly0.6https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/videos/are-there-patients-on-long-term-anticoagulant-treatment-who-might-benefit-from-prolonged-antiplatelet-therapy/2026-01-27T12:07:14+00:00weekly0.6https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/videos/how-should-severe-bleeding-be-managed-in-patients-on-dual-antithrombotic-therapy/2026-01-27T12:06:50+00:00weekly0.6https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/videos/controversies-on-choice-of-p2y12-inhibitor-are-the-recommendations-justifiable/2026-01-27T12:06:29+00:00weekly0.6https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/videos/should-another-prospective-randomised-trial-be-performed-for-ticagrelor-versus-prasugrel/2026-01-27T12:06:08+00:00weekly0.6https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/videos/roundtable-discussion-closing-remarks/2026-01-27T12:05:33+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/meet-professor-vlado-perkovic/2026-01-23T10:06:45+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/what-are-the-complications-and-burden-of-chronic-kidney-disease/2026-01-23T10:05:20+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/why-is-early-diagnosis-of-chronic-kidney-disease-important2/2026-01-23T10:04:27+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/what-are-the-concordant-comorbidities-and-risk-factors-associated-with-chronic-kidney-disease/2026-01-23T10:03:43+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/what-are-the-treatment-goals-for-chronic-kidney-disease/2026-01-23T10:02:58+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/what-are-the-current-recommendations-for-treating-chronic-kidney-disease-and-preserving-kidney-function/2026-01-23T09:54:06+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/what-are-the-recommendations-for-managing-comorbidities-in-patients-with-chronic-kidney-disease/2026-01-23T09:53:20+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/what-are-the-clinical-challenges-for-managing-chronic-kidney-disease-and-diabetic-kidney-disease/2026-01-23T09:52:33+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/what-are-the-risk-factors-for-chronic-kidney-disease/2026-01-23T09:51:42+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/what-are-the-most-recent-treatment-options-that-have-been-added-to-the-treatment-armamentarium-for-diabetic-and-non-diabetic-kidney-disease/2026-01-23T09:50:43+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/what-are-the-recommendations-for-optimising-the-management-of-comorbid-conditions-in-patients-at-risk-of-chronic-kidney-disease/2026-01-23T09:49:52+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion-videos/what-are-the-priorities-for-treatment-optimisation/2026-01-23T09:49:08+00:00weekly0.6https://www.medthority.com/medical-education/atopic-derm/publication-digests/abrocitinib-versus-placebo-or-dupilumab-for-atopic-dermatitis/2025-12-16T13:57:51+00:00weekly0.6https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/videos/why-is-it-important-to-know-about-the-latest-developments-in-hs/2026-01-14T10:20:59+00:00weekly0.6https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/videos/the-physical-and-psychological-impact-of-hs/2026-01-14T10:20:28+00:00weekly0.6https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/videos/severity-and-progression-risk-a-highly-variable-disease/2026-01-14T10:19:49+00:00weekly0.6https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/videos/the-immune-system-in-hs-pathophysiology/2026-01-14T10:18:35+00:00weekly0.6https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/videos/genetics-and-environmental-triggers-in-hs-risk/2026-01-14T10:17:57+00:00weekly0.6https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/videos/diagnostic-and-treatment-challenges/2026-01-14T10:16:27+00:00weekly0.6https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/videos/hs-treatment-goals/2026-01-14T10:15:49+00:00weekly0.6https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/videos/current-treatment-strategy-for-hs/2026-01-14T10:14:24+00:00weekly0.6https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/videos/emerging-treatment-approaches-for-hs/2026-01-14T10:13:51+00:00weekly0.6https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/videos/from-bench-to-clinic-facilitating-individualised-treatment/2026-01-14T10:11:28+00:00weekly0.6https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/videos/meet-dr-joslyn-kirby/2026-01-14T10:10:49+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/evidence-of-the-effectiveness-of-ret-inhibitors-for-treating-nsclc/2026-01-27T09:01:06+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/the-importance-of-molecular-testing-for-ret-inhibition-in-thyroid-cancer/2026-01-27T08:59:53+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/evidence-of-the-effectiveness-of-ret-inhibitors-for-treating-thyroid-cancer/2026-01-27T08:58:55+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/the-main-side-effects-of-ret-inhibitors-in-nsclc-and-how-to-address-them/2026-01-27T08:57:17+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/evidence-of-the-effectiveness-of-ret-inhibitors-for-treating-thyroid-cancer2/2026-01-27T08:56:23+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/the-challenges-of-patient-stratification-and-molecular-testing/2026-01-27T08:55:09+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/stratifying-nsclc-patients-for-ret-inhibitor-treatment/2026-01-27T08:54:11+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/real-world-challenges-of-thyroid-cancer-management-patient-stratification-and-molecular-testing-for-ret-alterations/2026-01-27T08:53:11+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/molecular-testing-techniques-for-ret-alteration-detection/2026-01-27T08:52:08+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/the-clinical-sample-journey/2026-01-27T08:51:58+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/nsclc-sample-requirements-for-ret-alteration-detection/2026-01-27T08:51:23+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/thyroid-cancer-sample-requirements-for-ret-alteration-detection/2026-01-27T08:50:49+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/molecular-testing-for-ret-alterations-navigating-the-results/2026-01-27T08:50:03+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/ret-status-in-nsclc-patients-testing-strategies-and-results-interpretation/2026-01-27T08:49:22+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/videos/ret-status-in-thyroid-cancer-patients-testing-strategies-and-results-interpretation/2026-01-27T08:48:18+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/introducing-dr-alexander-drilon/2026-01-27T09:20:05+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/the-importance-of-molecular-testing-for-ret-inhibitionin-nsclc/2026-01-27T09:19:38+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/the-relevance-of-ret-inhibition-for-nsclc-management/2026-01-27T09:19:13+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/evidence-of-the-effectiveness-of-ret-inhibitors-for-treating-nsclc/2026-01-27T09:18:52+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/what-ongoing-clinical-trials-are-underway-for-ret-inhibitors-in-nsclc/2026-01-27T09:18:26+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/the-main-side-effects-of-ret-inhibitors-in-nsclc-and-how-to-address-them/2026-01-27T09:18:01+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/stratifying-nsclc-patients-for-ret-inhibitor-treatment/2026-01-27T09:16:57+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/real-world-challenges-of-nsclc-management-patient-stratification-and-molecular-testing-for-ret-alterations/2026-01-27T09:16:25+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/ret-status-in-nsclc-patients-testing-strategies-and-results-interpretation/2026-01-27T09:15:49+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/introducing-professor-lori-wirth/2026-01-27T09:14:58+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/the-importance-of-molecular-testing-for-ret-inhibitionin-thyroid-cancer/2026-01-27T09:14:43+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/the-relevance-of-ret-inhibition-for-thyroid-cancer-management/2026-01-27T09:13:36+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/prevalence-of-ret-alterations-in-thyroid-cancers/2026-01-27T09:13:01+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/evidence-of-the-effectiveness-of-ret-inhibitors-for-treating-thyroid-cancer/2026-01-27T09:12:10+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/what-relevant-clinical-trials-are-currently-underway-in-medullary-thyroid-cancer/2026-01-27T09:11:30+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/the-main-side-effects-of-ret-inhibitors-in-thyroid-cancers-and-how-to-address-them/2026-01-27T09:10:55+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/stratifying-thyroid-cancer-patients-for-ret-inhibitor-treatment/2026-01-27T09:10:25+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/real-world-challenges-of-thyroid-cancer-management-patient-stratification-and-molecular-testing-for-ret-alterations/2026-01-27T09:09:52+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/ret-status-in-thyroid-cancer-patients-testing-strategies-and-results-interpretation/2026-01-27T09:09:10+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/introducing-professor-fernando-lopez-rios/2026-01-27T09:05:15+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/prevalence-of-ret-alterations-in-nsclc-and-thyroid-cancers/2026-01-27T09:05:03+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/the-importance-of-molecular-testing-for-ret-alterations/2026-01-27T09:04:55+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/the-challenges-of-patient-stratification-and-molecular-testing-for-ret-alterations/2026-01-27T09:04:48+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/molecular-testing-techniques-for-ret-alteration-detection/2026-01-27T09:04:39+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/nsclc-sample-requirements-for-ret-alteration-detection/2026-01-27T09:04:23+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/thyroid-cancer-sample-requirements-for-ret-alteration-detection/2026-01-27T09:04:03+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/the-clinical-sample-journey-for-assessing-ret-alterations/2026-01-27T09:03:11+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion-videos/molecular-testing-for-ret-alteration-navigating-the-results/2026-01-27T09:05:49+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/what-are-current-best-practices-for-assessing-osteoarthritis-associated-pain/2026-01-27T15:43:36+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/should-clinicians-apply-outcome-measures-in-clinical-trials-to-assess-osteoarthritis-associated-pain/2026-01-27T15:43:30+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/how-should-central-sensitisation-be-assessed-in-patients-with-osteoarthritis-associated-pain/2026-01-27T15:43:23+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/have-you-used-digital-collection-methods-to-aid-clinical-assessment-of-osteoarthritis/2026-01-27T15:43:16+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/what-are-key-considerations-in-the-management-of-osteoarthritis-associated-pain/2026-01-27T15:43:09+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/what-treatment-options-are-most-suitable-for-managing-osteoarthritis-associated-pain-in-different-body-joints/2026-01-27T15:43:02+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/is-intra-articular-therapy-iat-recommended-for-managing-osteoarthritis-associated-pain-in-small-joints/2026-01-27T15:42:56+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/does-eular-report-data-on-new-or-emerging-pharmacological-treatments-for-osteoarthritis-associated-pain/2026-01-27T15:42:48+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/what-strategies-best-motivate-patients-to-adhere-to-their-treatments-or-lifestyle-changes-such-as-weight-loss/2026-01-27T15:42:39+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/are-personalised-approaches-to-managing-osteoarthritis-associated-pain-cost-effective/2026-01-27T15:42:33+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/do-guidelines-recommend-treatments-for-managing-central-sensitisation-in-osteoarthritis-associated-pain/2026-01-27T15:42:27+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/should-sex-differences-be-investigated-more-to-identify-new-treatments-for-osteoarthritis-associated-pain/2026-01-27T15:42:20+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/is-hormone-replacement-therapy-hrt-a-possible-treatment-for-hand-osteoarthritis/2026-01-27T15:42:14+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/are-patients-with-osteoarthritis-associated-pain-at-risk-of-serious-adverse-events-if-they-receive-multiple-corticosteroid-injections/2026-01-27T15:42:09+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/what-are-the-current-investigational-treatments-for-osteoarthritis-associated-pain/2026-01-27T15:42:04+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/is-it-ethical-to-give-investigational-treatments-to-patients-at-early-stages-of-osteoarthritis-development/2026-01-27T15:41:57+00:00weekly0.6https://www.medthority.com/medical-education/osteoarthritis-associated-pain/videos/what-is-the-difference-between-early-and-late-osteoarthritis/2026-01-27T15:41:51+00:00weekly0.6https://www.medthority.com/medical-education/improving-treatment-options-childhood-psoriasis/eadv-2021-videos/welcome-to-eadv-2021-paediatric-psoriasis-symposium/2026-01-13T08:53:25+00:00weekly0.6https://www.medthority.com/medical-education/improving-treatment-options-childhood-psoriasis/eadv-2021-videos/how-are-new-treatments-addressing-unmet-needs-in-paediatric-psoriasis/2026-01-13T08:46:16+00:00weekly0.6https://www.medthority.com/medical-education/improving-treatment-options-childhood-psoriasis/eadv-2021-videos/how-do-we-differentiate-between-the-emerging-biologic-treatments-for-paediatric-psoriasis/2026-01-13T08:45:28+00:00weekly0.6https://www.medthority.com/medical-education/improving-treatment-options-childhood-psoriasis/eadv-2021-videos/achieving-long-term-clearance-in-paediatric-psoriasis/2026-01-13T08:44:44+00:00weekly0.6https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/publication-digest/dapagliflozin-in-patients-with-chronic-kidney-disease/2026-01-16T10:10:19+00:00weekly0.6https://www.medthority.com/medical-education/improving-treatment-options-childhood-psoriasis/eadv-2021-videos/live-qa/2026-01-13T08:43:28+00:00weekly0.6https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/publication-digest/efficacy-of-selpercatinib-in-ret-fusion-positive-non-small-cell-lung-cancer/2026-01-27T09:27:49+00:00weekly0.6https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/expert-opinion/dr-noel-baxter/2025-12-02T14:12:04+00:00weekly0.6https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/expert-opinion/darush-attar-zadeh/2025-12-02T14:11:30+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/plasma-volume-expansion/2026-01-13T13:30:52+00:00weekly0.6https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/videos/leslie-coping-with-stress/2025-12-02T14:52:41+00:00weekly0.6https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/videos/peter-multiple-comorbidities/2025-12-02T14:52:09+00:00weekly0.6https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/videos/philip-relapsed-smoker/2025-12-02T14:51:19+00:00weekly0.6https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/videos/alexander-not-yet-ready-to-quit/2025-12-02T14:50:51+00:00weekly0.6https://www.medthority.com/medical-education/atopic-derm/aad-2022/what-are-the-latest-findings-regarding-safety-and-efficacy-of-oral-jak-inhibitors-for-atopic-dermatitis-treatment/2026-01-27T16:01:18+00:00weekly0.6https://www.medthority.com/medical-education/atopic-derm/aad-2022/what-factors-do-dermatologists-need-to-consider-when-selecting-a-jak-inhibitor-for-treatment-of-atopic-dermatitis/2026-01-27T16:01:08+00:00weekly0.6https://www.medthority.com/medical-education/atopic-derm/aad-2022/what-advice-can-you-give-to-dermatologists-when-discussing-treatment-options-with-their-patients/2026-01-27T16:01:00+00:00weekly0.6https://www.medthority.com/medical-education/glaucoma-learning-zone/publication-digests/brinzolamidebrimonidine-fixed-dose-combination/2025-12-05T09:41:16+00:00weekly0.6https://www.medthority.com/medical-education/glaucoma-learning-zone/publication-digests/brinzolamide--timolol-vs-dorzolamide--timolol-fixed-combinations-in-oag/2025-12-05T09:43:12+00:00weekly0.6https://www.medthority.com/medical-education/glaucoma-learning-zone/publication-digests/brinzolamide-brimonidine-fixed-combination/2025-12-05T09:41:57+00:00weekly0.6https://www.medthority.com/medical-education/glaucoma-learning-zone/publication-digests/rho-kinase-inhibitor/2025-12-05T09:41:38+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/how-is-supportive-care-different-in-the-geriatric-patient/2026-01-22T11:14:20+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/dr-aarpo-defines-these-types-of-care/2026-01-22T11:05:29+00:00weekly0.6https://www.medthority.com/medical-education/atopic-derm/publication-digests/results-from-head-to-head-phase-3-atopic-dermatitis-clinical-trial-of-systemic-treatments/2025-12-16T13:52:36+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/what-is-supportive-care/2026-01-22T10:57:37+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/why-is-supportive-care-crucial-to-cancer-management/2026-01-22T10:54:53+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/what-barriers-are-preventing-implementation-of-supportive-care-models/2026-01-22T10:52:05+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/what-is-the-structure-and-function-of-the-multidisciplinary-team-in-supportive-care/2026-01-22T10:49:13+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/what-is-the-difference-between-supportive-care-palliative-care-and-patient-centred-care2/2026-01-22T10:46:48+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/how-is-supportive-care-different-in-the-geriatric-patient2/2026-01-22T10:44:01+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/how-do-the-side-effects-of-cancer-treatment-impact-on-patient-quality-of-life/2026-02-23T15:51:46+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/are-novel-cancer-treatments-associated-with-different-side-effects/2026-02-23T15:45:41+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/what-are-the-haematological-side-effects-of-cancer-treatment-and-how-are-these-managed/2026-01-20T16:21:06+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/what-are-the-gastrointestinal-side-effects-of-cancer-treatment/2026-01-20T15:20:48+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/what-are-the-cardiovascular-and-respiratory-side-effects-of-cancer-treatment/2026-01-20T15:18:02+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/what-are-the-neurological-side-effects-of-cancer-treatment/2026-01-20T15:15:14+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/management-guidelines-for-cancer-associate-thrombosis/2026-01-20T15:10:02+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/management-guidelines-for-nausea-and-vomiting-following-cancer-treatment/2026-01-20T15:11:37+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/guideline-recommended-management-of-febrile-and-non-febrile-neutropenia/2026-01-19T14:39:44+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/guideline-recommendations-for-management-of-fatigue-in-cancer-patients/2026-01-19T14:35:34+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/introduction-to-dr-matti-aapro/2026-01-22T11:03:00+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/videos/introduction-to-dr-gary-lyman/2026-01-22T11:00:09+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/can-biosimilars-be-relied-upon-to-achieve-similar-treatment-outcomes-to-reference-biologics/2026-01-27T16:10:05+00:00weekly0.6https://www.medthority.com/medical-education/respiratory-syncytial-virus/wonca-2022-videos/what-were-the-most-important-discussions-focused-on-respiratory-diseases-to-emerge-from-wonca-2022-and-why/2026-01-27T14:44:35+00:00weekly0.6https://www.medthority.com/medical-education/respiratory-syncytial-virus/wonca-2022-videos/what-is-your-take-home-message-from-wonca-2022/2026-01-27T14:44:17+00:00weekly0.6https://www.medthority.com/medical-education/respiratory-syncytial-virus/wonca-2022-videos/how-has-telemedicine-affected-rsv-diagnosis/2026-01-27T14:43:59+00:00weekly0.6https://www.medthority.com/medical-education/respiratory-syncytial-virus/wonca-2022-videos/what-are-the-new-advances-in-primary-care-respiratory-medicine-and-what-are-the-implications-for-rsv-patients/2026-01-27T14:43:43+00:00weekly0.6https://www.medthority.com/medical-education/respiratory-syncytial-virus/wonca-2022-videos/how-is-antimicrobial-resistance-affecting-the-treatment-of-rsv-and-how-can-we-tackle-it/2026-01-27T14:42:13+00:00weekly0.6https://www.medthority.com/medical-education/respiratory-syncytial-virus/wonca-2022-videos/what-are-the-new-approaches-to-primary-care-research-regarding-respiratory-infections-and-how-will-this-affect-rsv-in-primary-care/2026-01-27T14:43:16+00:00weekly0.6https://www.medthority.com/medical-education/respiratory-syncytial-virus/wonca-2022-videos/any-final-remarks-on-the-content-of-the-congress-relevant-to-the-diagnosis-and-management-of-rsv/2026-01-27T14:42:56+00:00weekly0.6https://www.medthority.com/medical-education/respiratory-syncytial-virus/wonca-2022-videos/meet-the-expert/2026-01-27T14:42:39+00:00weekly0.6https://www.medthority.com/medical-education/atopic-derm/publication-digests/baricitinib-rapidly-improves-skin-pain/2025-12-16T13:56:20+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/meet-dr-ashish-sharma-and-hear-about-his-experience-in-treating-retinal-disease/2026-01-27T16:12:22+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/what-is-a-biosimilar/2026-01-27T16:12:18+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/what-are-the-benefits-of-ophthalmology-biosimilars-for-clinicians-and-patients/2026-01-27T16:12:13+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/how-rigorous-is-the-biosimilar-development-process/2026-01-27T16:12:08+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/are-biosimilars-trustworthy/2026-01-27T16:12:03+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/how-does-the-biosimilar-development-compare-to-that-of-reference-biologics/2026-01-27T16:11:57+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/why-have-biosimilars-only-recently-arrived-on-the-market-for-retinal-disease/2026-01-27T16:11:53+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/which-anti-vegf-biosimilars-are-approved-in-europe-and-the-us-and-what-others-are-in-development/2026-01-27T16:11:48+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/how-does-efficacy-of-anti-vegf-biosimilars-compare-to-that-of-their-reference-biologics-in-retinal-disease/2026-01-27T16:11:44+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/how-does-the-safety-profile-of-anti-vegf-biosimilars-compare-to-their-reference-biologics/2026-01-27T16:11:39+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/can-biosimilars-improve-access-to-care-for-patients-with-retinal-disease/2026-01-27T16:11:34+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/is-there-evidence-for-a-correlation-between-delayed-treatment-and-visual-acuity-in-retinal-disease/2026-01-27T16:11:29+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/what-are-some-key-considerations-when-switching-from-a-reference-medicine-to-a-biosimilar-for-retinal-disease/2026-01-27T16:11:24+00:00weekly0.6https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/videos/what-are-some-key-points-to-discuss-with-patients-when-considering-a-biosimilar-for-retinal-disease/2026-01-27T16:11:18+00:00weekly0.6https://www.medthority.com/medical-education/atopic-derm/publication-digests/efficacy-and-safety-profile-of-jak-inhibitor-for-atopic-dermatitis-from-two-replicate-trials/2025-12-16T13:56:44+00:00weekly0.6https://www.medthority.com/medical-education/atopic-derm/publication-digests/a-jak-inhibitor-for-atopic-dermatitis-a-randomised-clinical-trial/2025-12-16T13:57:23+00:00weekly0.6https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/efficacy-and-safety/inadequate-response-to-initial-anti-tnf-therapy-in-ra/2026-01-19T10:43:56+00:00weekly0.6https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/efficacy-and-safety/non-response-or-loss-of-response-to-anti-tnfs-in-ibd-whats-the-cause/2026-01-19T10:41:58+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/key-insights-from-ectrims-2022-with-dr-victoria-leavitt/2025-12-11T09:34:40+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/what-were-some-key-highlights-from-ectrims-2022-that-you-consider-important-for-clinical-practice/2025-12-11T09:34:52+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/what-is-the-latest-evidence-on-new-generation-therapies-for-first-line-intervention-in-ms/2025-12-11T09:34:29+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/in-your-own-practice-how-do-you-approach-treatment-selection-for-people-with-ms/2025-12-11T09:34:19+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/patient-perspective---thoughts-on-current-range-of-treatments-for-management-of-ms-and-considering-the-risks-of-treatment-versus-the-risks-of-ms-progression/2025-12-11T09:34:06+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/should-clinicians-focus-on-minimising-disease-progression-from-the-point-of-diagnosis/2025-12-11T09:33:55+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/what-are-key-considerations-for-pregnancy-and-family-planning-for-patients-with-multiple-sclerosis/2025-12-11T09:33:45+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/what-is-the-latest-evidence-on-the-safety-profile-of-anti-cd20-therapies-in-ms/2025-12-11T09:33:34+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/how-has-management-of-ms-evolved-since-you-were-diagnosed/2025-12-11T09:33:17+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/what-can-healthcare-professionals-do-to-improve-care-for-people-with-multiple-sclerosis-and-improve-management-of-the-disease/2025-12-11T09:33:07+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/what-can-healthcare-professionals-do-to-improve-care-for-people-with-multiple-sclerosis-and-improve-management-of-the-disease2/2025-12-11T09:32:54+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/do-people-with-ms-perceive-the-risk-of-disease-as-greater-or-lesser-than-the-risk-associated-with-the-treatment/2025-12-11T09:32:39+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/what-evidence-from-ectrims-2022-on-cognitive-impairment-in-ms-is-likely-to-have-the-most-impact-on-management/2025-12-11T09:32:27+00:00weekly0.6https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/videos/what-approaches-can-help-to-address-cognitive-changes-in-people-with-ms/2025-12-11T09:11:49+00:00weekly0.6https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/congress-highlights/ueg-2020-congress-highlights/2026-01-19T11:11:05+00:00weekly0.6https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/congress-highlights/acr-2022-congress-highlights/2026-01-19T10:56:46+00:00weekly0.6https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/2022-webinar-videos/how-do-parp-inhibitors-fit-within-the-ovarian-treatment-landscape/2026-01-27T15:30:32+00:00weekly0.6https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/2022-webinar-videos/are-parp-inhibitors-right-for-your-patient-with-ovarian-cancer/2026-01-27T15:30:08+00:00weekly0.6https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/2022-webinar-videos/whats-next-parp-inhibitor-combination-treatments-in-different-clinical-settings-for-ovarian-cancer/2026-01-27T15:29:53+00:00weekly0.6https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/2022-webinar-videos/qa-session-with-expert-panel/2026-01-27T15:29:38+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/understanding-alopecia-areata/in-terms-of-personal-wellbeing-what-aspect-of-alopecia-areata-affects-you-the-most/2025-12-18T11:01:31+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/understanding-alopecia-areata/how-has-alopecia-areata-affected-your-social-interactions/2025-12-18T11:00:57+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/understanding-alopecia-areata/what-impact-has-alopecia-areata-had-on-your-day-to-day-life-has-it-stopped-you-doing-anything/2025-12-18T11:00:30+00:00weekly0.6https://www.medthority.com/medical-education/lipid-management-in-ascvd/publication-digest/lipoproteina-in-atherosclerotic-cardiovascular-disease-and-aortic-stenosis-a-european-atherosclerosis-society-consensus-statement/2026-01-15T10:07:56+00:00weekly0.6https://www.medthority.com/medical-education/lipid-management-in-ascvd/publication-digest/the-orion-10-and-orion-11-trials/2026-01-15T10:09:57+00:00weekly0.6https://www.medthority.com/medical-education/glaucoma-learning-zone/publication-digests/metabolomics-in-primary-open-angle-glaucoma-a-systematic-review-and-meta-analysis/2025-12-05T09:43:36+00:00weekly0.6https://www.medthority.com/medical-education/lipid-management-in-ascvd/publication-digest/the-da-vinci-study/2026-01-15T10:11:04+00:00weekly0.6https://www.medthority.com/medical-education/future-breast-cancer-2024/transcripts/transcript-eleanor-diarrhoea-manageable-in-real-world-study-of-neratinib-in-ebc/2025-10-13T09:42:40+00:00weekly0.6https://www.medthority.com/medical-education/future-breast-cancer-2024/transcripts/transcript-communicating-diarrhoea-risk/2025-10-13T09:42:26+00:00weekly0.6https://www.medthority.com/medical-education/future-breast-cancer-2024/transcripts/transcript-key-trial-updates-from-esmo-breast-cancer-2024/2025-10-13T09:42:11+00:00weekly0.6https://www.medthority.com/medical-education/future-breast-cancer-2024/transcripts/transcript-transforming-her2-positive-breast-cancer-care-the-federica-study/2025-10-13T09:41:54+00:00weekly0.6https://www.medthority.com/medical-education/future-breast-cancer-2024/transcripts/transcript-early-breast-cancer-highlights-presented-at-esmo-2024/2025-10-13T09:41:30+00:00weekly0.6https://www.medthority.com/medical-education/future-breast-cancer-2024/transcripts/transcript-future-developments-in-breast-cancer-treatment-art-and-cdk46i/2025-10-13T09:40:50+00:00weekly0.6https://www.medthority.com/medical-education/future-breast-cancer-2024/transcripts/transcript-predicting-pcr-and-survival-in-her2-breast-cancer-using-her2dx-test/2025-10-13T09:40:31+00:00weekly0.6https://www.medthority.com/medical-education/future-breast-cancer-2024/transcripts/transcript-latest-updates-from-the-text-and-soft-clinical-trials/2025-10-13T09:40:07+00:00weekly0.6https://www.medthority.com/medical-education/future-breast-cancer-2024/transcripts/transcript-premenopausal-vs-postmenopausal-outcomes-in-the-combined-soft-and-text-trials/2025-10-13T09:39:47+00:00weekly0.6https://www.medthority.com/medical-education/future-breast-cancer-2024/transcripts/transcript-underrated-data-bmi-based-chemotherapy-dosing-and-trastuzumab-deruxtecan-for-ild/2025-10-13T09:39:29+00:00weekly0.6https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transcripts/transcript-living-with-mg-at-work-and-at-home/2025-12-11T10:24:18+00:00weekly0.6https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transcripts/transcript-unmet-needs-the-patient-perspective/2025-12-11T10:24:00+00:00weekly0.6https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transcripts/transcript-the-push-for-better-mg-care/2025-12-11T10:23:41+00:00weekly0.6https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transcripts/transcript-living-with-mg-advice-from-a-patient/2025-12-11T10:23:16+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-what-is-the-difference-between-supportive-palliative-and-patient-centred-care222/2026-01-22T13:21:28+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-haematological-side-effects/2026-01-22T12:00:51+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-gastrointestinal-side-effects/2026-01-22T11:56:15+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-cardiovascular-side-effects/2026-01-22T11:50:29+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-neurological-and-muscular-side-effects/2026-01-22T11:42:00+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-fatigue/2026-01-22T11:39:50+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-thrombosis/2026-01-22T11:37:29+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-febrile-and-non-febrile-neutropenia/2026-01-22T11:24:19+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-nausea-and-vomiting/2026-01-22T11:17:41+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/why-is-supportive-care-critical-to-cancer-management/2026-01-22T13:42:25+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-what-is-supportive-care-in-cancer/2026-01-22T13:38:01+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-what-barriers-are-preventing-implementation-of-supportive-care-models/2026-01-22T13:35:21+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-what-barriers-are-preventing-implementation-of-supportive-care-models2/2026-01-22T13:33:00+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-what-is-the-difference-between-supportive-palliative-and-patient-centred-care/2026-01-22T13:30:29+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-what-is-the-difference-between-supportive-palliative-and-patient-centred-care2/2026-01-22T13:28:01+00:00weekly0.6https://www.medthority.com/medical-education/supportive-care-in-oncology/transcripts/transcript-what-is-the-difference-between-supportive-palliative-and-patient-centred-care22/2026-01-22T13:24:33+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-dr-juliana-jewel-kling-intro/2025-09-01T07:15:29+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-the-impact-of-vms-on-womens-daily-lives/2025-09-01T07:15:11+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-unmet-needs-in-vms/2025-09-01T07:14:56+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-vms-and-mental-health/2025-09-01T07:14:39+00:00weekly0.6https://www.medthority.com/medical-education/vms-hub/transcripts/transcript-addressing-the-mental-health-needs-of-women-with-vms/2025-09-01T07:14:24+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/transcripts/transcript-the-evolving-landscape-of-lymphoma-treatment/2026-03-12T12:58:35+00:00weekly0.6https://www.medthority.com/medical-education/modern-management-rrmm/transcripts/transcript-real-world-rrmm-data-comy/2025-08-04T12:28:38+00:00weekly0.6https://www.medthority.com/medical-education/modern-management-rrmm/transcripts/transcript-frailty-in-rrmm-comy-2024/2025-08-04T12:28:17+00:00weekly0.6https://www.medthority.com/medical-education/modern-management-rrmm/transcripts/transcript-treatment-advances-in-rrmm/2025-08-04T12:27:46+00:00weekly0.6https://www.medthority.com/medical-education/modern-management-rrmm/transcripts/transcript-treatment-selection/2025-08-04T12:27:27+00:00weekly0.6https://www.medthority.com/medical-education/modern-management-rrmm/transcripts/transcript-controversies-comy-2024/2025-08-04T12:27:12+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/highlights-from-aad-2024/transcript-optimising-safe-use-of-jak-inhibitors-for-alopecia-areata/2025-12-18T10:30:24+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/highlights-from-aad-2024/transcript-the-allegro-clinical-trial/2025-12-18T10:29:59+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/highlights-from-aad-2024/transcript-predictors-of-treatment-response-for-alopecia-areata/2025-12-18T10:29:32+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/highlights-from-aad-2024/transcript-psychosocial-needs-of-young-people-and-children-with-alopecia-areata/2025-12-18T10:29:08+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/highlights-from-aad-2024/transcript-how-to-balance-coping-with-hair-loss-and-wanting-hair-regrowth/2025-12-18T10:28:45+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/highlights-from-aad-2024/transcript-aad-2024-highlights/2025-12-18T10:28:21+00:00weekly0.6https://www.medthority.com/medical-education/roundtable-discussion-biologics-in-plaque-psoriasis/transcripts/transcript-real-world-evidence-update/2025-08-07T11:20:12+00:00weekly0.6https://www.medthority.com/medical-education/roundtable-discussion-biologics-in-plaque-psoriasis/transcripts/transcript-choosing-the-right-treatment-for-the-right-patient/2025-08-07T11:19:30+00:00weekly0.6https://www.medthority.com/medical-education/roundtable-discussion-biologics-in-plaque-psoriasis/transcripts/transcript-switching-and-combination-therapies-to-optimise-response/2025-08-07T11:18:33+00:00weekly0.6https://www.medthority.com/medical-education/roundtable-discussion-biologics-in-plaque-psoriasis/transcripts/transcript-an-open-discussion/2025-08-07T11:18:19+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-establishing-a-positive-patientdoctor-relationship/2025-12-19T09:53:05+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-challenges-in-delivering-optimal-af-care/2025-12-19T09:52:19+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-closing-clinical-gaps-in-af-management/2025-12-19T09:56:25+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-what-patient-outcomes-would-improve-if-clinical-gaps-were-closed/2025-12-19T09:55:44+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-including-patients-in-shared-clinical-decision-making/2025-12-19T09:55:00+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-helping-clinicians-understand-the-patient-experience-of-af/2025-12-19T09:53:46+00:00weekly0.6https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transcripts/transcript-a-case-of-mg-post-thymectomy/2025-12-11T10:24:34+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/transcripts/transcript-comparing-treatment-options-in-children/2026-03-12T11:11:32+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/transcripts/transcript-real-world-evidence-and-decision-making/2026-03-12T11:11:12+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/transcripts/transcript-health-economics-and-biosimilars/2026-03-12T11:10:53+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/transcripts/transcript-diagnosis-and-management-in-children/2026-03-12T11:10:30+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/transcripts/transcript-challenges-and-unmet-needs-in-children/2026-03-12T11:10:08+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/transcripts/transcript-expert-discussion-diagnostic-thresholds-optimal-gh-dose-and-high-risk-groups/2026-03-12T11:09:47+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-what-are-the-tenets-of-the-abc-pathway-and-their-clinical-implications-for-managing-af/2025-12-19T10:15:07+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-what-are-key-factors-to-consider-when-selecting-an-anticoagulant-for-vte-treatment/2025-12-19T10:14:21+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-what-factors-influence-choice-of-anticoagulant-for-secondary-prevention/2025-12-19T10:13:38+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-what-are-the-benefits-of-screening-for-af/2025-12-19T10:12:51+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-what-are-the-recommendations-for-oral-anticoagulant-therapy-for-stroke-prevention-in-patients-with-atrial-fibrillation/2025-12-19T10:12:02+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-what-is-the-abc-pathway-for-holistic-management-of-patients-with-af/2025-12-19T10:11:20+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-do-real-world-data-demonstrate-improved-patient-outcomes-when-the-abc-pathway-is-implemented/2025-12-19T10:10:35+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-why-is-the-abc-pathway-necessary-when-oacs-have-proven-efficacy-in-stroke-prevention/2025-12-19T10:09:52+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-how-would-you-recommend-hcps-implement-the-abc-pathway-in-clinical-practice/2025-12-19T10:08:39+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-in-patients-with-multimorbidities-should-one-condition-take-priority-of-the-others/2025-12-19T10:07:56+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-real-world-research-and-why-it-is-medically-important/2025-12-19T10:07:18+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-cohort-studies-on-the-effectiveness-and-safety-of-doacs-for-vte/2025-12-19T10:06:34+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-cross-sectional-research-investigating-doacs-for-vte/2025-12-19T10:05:36+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-real-world-evidence-from-patient-registry-studies-on-the-effectiveness-and-safety-of-doacs-for-vte/2025-12-19T10:04:49+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-administrative-and-healthcare-database-studies-on-vte/2025-12-19T10:04:03+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-do-electronic-health-record-studies-on-doacs-for-vte-compare-well-with-randomised-clinical-trials/2025-12-19T10:03:16+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-key-messages-on-real-world-research-for-vte/2025-12-19T10:02:33+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-why-is-it-important-to-assess-a-patients-risk-of-vte/2025-12-19T10:01:53+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-what-are-some-key-changes-to-vte-management-from-guideline-updates-in-2019-2021/2025-12-19T10:00:42+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-when-should-a-patients-risk-of-thrombosis-be-assessed/2025-12-19T10:00:03+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-when-should-a-patients-risk-of-bleeding-be-assessed/2025-12-19T09:58:43+00:00weekly0.6https://www.medthority.com/medical-education/think-thrombosis/transcripts/transcript-how-should-duration-of-anticoagulation-treatment-be-determined-for-each-patient/2025-12-19T09:57:25+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-surgery-and-barriers/2025-12-16T15:10:48+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-ehsf-2024-key-developments/2025-12-16T15:10:09+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-comorbidities-and-patient-provider-viewpoints/2025-12-16T15:09:11+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-real-world-data-and-emerging-medications/2025-12-16T15:08:24+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-emerging-treatments-and-further-research/2025-12-16T15:07:19+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-short-term-treatment-landscape-and-importance-of-educational-activity/2025-12-16T15:03:02+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-the-debate-between-hiscr-and-ihs4/2025-12-16T15:02:38+00:00weekly0.6https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/transcripts/transcript-eadv-2024-new-research/2025-12-16T15:01:38+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/the-future-of-alopecia-areata/what-unmet-needs-of-alopecia-areata-management-matter-most-to-you/2025-12-18T10:26:41+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/the-future-of-alopecia-areata/key-considerations-for-healthcare-professionals/2025-12-18T10:26:14+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/ghd-expert-roundtable-old/expert-discussion/2025-12-15T11:11:56+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/ghd-expert-roundtable-old/challenges-and-unmet-needs-in-children/2025-12-15T11:11:21+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/ghd-expert-roundtable-old/diagnosis-and-management-in-children/2025-12-15T11:10:53+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/ghd-expert-roundtable-old/health-economics-and-biosimilars/2025-12-15T11:10:22+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/ghd-expert-roundtable-old/real-world-evidence-and-decision-making/2025-12-15T11:09:48+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/ghd-expert-roundtable-old/comparing-treatment-options/2025-12-15T11:09:20+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/ghd-expert-roundtable-old/welcome-and-introduction/2025-12-15T11:08:20+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/covid-19s-impact-on-psoriasis-clinical-practice-and-on-biologics-with-reduced-dosing-schedules/2026-01-27T14:28:34+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/long-term-il-23-inhibitor-safety-and-efficacy-data-in-vulnerable-psoriasis-patient-groups/2026-01-27T14:28:47+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/how-does-the-long-term-safety-and-efficacy-of-il-23-inhibitors-compare-to-older-biologic-agents-for-psoriasis/2026-01-27T14:28:55+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/has-our-understanding-of-the-long-term-safety-of-il-23-inhibitors-improved-since-2021/2026-01-27T14:29:05+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/how-might-recent-long-term-safety-and-efficacy-data-on-il-23-inhibitors-impact-psoriasis-clinical-practice/2026-01-27T14:29:13+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/how-important-is-maintenance-of-response-from-the-perspective-of-people-with-psoriasis/2026-01-27T14:29:29+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/relative-medication-durability-and-medication-choice-for-people-with-moderate-to-severe-psoriasis/2026-01-27T14:29:39+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/are-there-new-insights-on-the-long-term-efficacy-of-biologics-for-psoriasis/2026-01-27T14:29:49+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/in-the-resurface-psoriasis-study-how-do-the-il-23p-19-inhibitors-compare-in-the-real-world-population/2026-01-27T14:30:00+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/benefits-of-inhibiting-il-23p19-compared-to-il-12-or-il-23-in-moderate-to-severe-psoriasis/2026-01-27T14:30:09+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/in-the-resurface-psoriasis-study-were-new-safety-signals-evident-only-after-long-term-use-of-tildrakizumab/2026-01-27T14:30:18+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/how-important-are-absolute-pasi-scores-compared-to-pasi-75-90-or-100/2026-01-27T14:30:27+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/long-term-tildrakizumab-efficacy-in-the-resurface-psoriasis-study/2026-01-27T14:30:36+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/why-is-long-term-efficacy-and-safety-biologics-data-important-for-treating-psoriasis/2026-01-27T14:30:55+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/what-should-you-consider-in-managing-patients-with-moderately-severe-psoriasis/2026-01-27T14:31:15+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment-videos/are-treatment-options-limited-for-patients-with-localised-psoriasis/2026-01-27T14:31:25+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/qa-discussion/2026-01-27T14:31:43+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/dr-anthony-bewley-summary/2026-01-27T14:32:09+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/how-has-calbdp-pad-cream-performed-in-clinical-trials/2026-01-27T14:32:19+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/what-can-be-done-to-remove-barriers-to-treatment-adherence-in-people-with-psoriasis/2026-01-27T14:32:28+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/why-is-shared-decision-making-important-when-selecting-a-topical-treatment-for-psoriasis/2026-01-27T14:32:38+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/what-factors-impact-adherence-to-psoriasis-treatment/2026-01-27T14:32:47+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/what-can-be-the-role-of-dermatologists-in-the-psychological-aspects-of-psoriasis/2026-01-27T14:32:57+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/what-is-the-psychologicalpsychiatric-impact-of-psoriasis/2026-01-27T14:33:08+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/topical-therapy-for-psoriasis-current-knowledge-and-future-research/2026-01-27T14:33:19+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/can-topical-therapies-be-used-to-treat-severe-forms-of-psoriasis/2026-01-27T14:33:30+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/what-are-the-benefits-of-combining-topical-and-systemic-therapy-in-psoriasis/2026-01-27T14:33:51+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/what-does-real-world-evidence-tell-us-about-long-term-topical-treatment-of-psoriasis/2026-01-27T14:34:03+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/what-is-the-role-of-topical-treatment-in-the-management-of-psoriasis/2026-01-27T14:34:13+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/what-is-the-burden-of-disease-among-people-with-psoriasis/2026-01-27T14:34:51+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/are-we-providing-patients-with-adequate-treatment-for-their-psoriasis/2026-01-27T14:35:06+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-symposium/welcome-and-introduction/2026-01-27T14:35:24+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/patient-wellbeing-videos/key-takeaway-from-jessica-towner-a-psoriasis-patient-advocate/2026-01-27T14:27:14+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/patient-wellbeing-videos/key-takeaway-from-associate-professor-jordi-quoidbach-a-wellbeing-expert/2026-01-27T14:27:22+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/patient-wellbeing-videos/key-takeaway-from-professor-ulrich-mrowietz-a-leading-dermatologist/2026-01-27T14:27:30+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/patient-wellbeing-videos/for-dermatologists-psychological-approaches-to-supporting-their-psoriasis-patients/2026-01-27T14:27:40+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/patient-wellbeing-videos/effective-alternatives-to-medications-to-treat-stress-induced-worsening-of-psoriasis/2026-01-27T14:27:50+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/patient-wellbeing-videos/mental-health-comorbidities-and-their-impact-on-people-with-psoriasis/2026-01-27T14:28:00+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/patient-wellbeing-videos/clinical-discussion-of-wellbeing-in-people-with-psoriasis/2026-01-27T14:28:12+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/real-world-evidence-videos/Is-the-WHO-5-questionnaire-new-in-medicine/2026-01-27T14:36:27+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/real-world-evidence-videos/What-is-the-POSITIVE-study-and-what-makes-it-evolutionary-and-unique-among-psoriasis-studies/2026-01-27T14:36:33+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/real-world-evidence-videos/Do-patient-see-a-difference-when-filling-out-a-negative-versus-a-positive-questionnaire/2026-01-27T14:36:40+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/real-world-evidence-videos/how-are-measurement-tools/2026-01-27T14:36:48+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/real-world-evidence-videos/How-should-physicians-assess-the-impact-of-psoriasis-in-a-more-person-centric-way/2026-01-27T14:36:55+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/real-world-evidence-videos/is-real-world-evidence-for-biologic-treatment-efficacy-sufficient-to-aid-practitioners-and-patients-in-shared-decision-making2/2026-01-27T14:37:02+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/real-world-evidence-videos/Does-real-world-data-inform-us-about-biologic-drug-survival-and-relapse-rates/2026-01-27T14:37:09+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/real-world-evidence-videos/Does-real-world-data/2026-01-27T14:37:16+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/real-world-evidence-videos/video-12/2026-01-27T14:37:25+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2022/the-biggest-take-away-from-the-symposium/2026-01-27T14:37:37+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2022/key-take-aways-for-attendees-of-eadv-2022/2026-01-27T14:37:45+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2022/the-must-watch-sessions-at-eadv-2022/2026-01-27T14:37:52+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2022/the-patient-perspective-high-on-the-agenda-at-eadv-2022/2026-01-27T14:37:59+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2022/how-happy-were-you-to-actually-find-a-treatment-that-you-felt-you-had-long-term-control-with/2026-01-27T14:38:06+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2022/the-importance-of-shared-decision-making-the-patient-perspective/2026-01-27T14:38:14+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2022/shared-decision-making-the-importance-of-implementing-theory-into-practice/2026-01-27T14:38:23+00:00weekly0.6https://www.medthority.com/medical-education/lipid-management-in-ascvd/publication-digest/bempedoic-acid-and-cardiovascular-outcomes-in-statin-intolerant-patients/2026-01-15T10:12:14+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/people-centred-care-in-psoriasis/symposium-evaluation/2025-12-09T09:57:17+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/absolute-pasi-scores/2026-01-27T14:16:29+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/links-between-cardiology-and-dermatology-in-the-setting-of-psoriasis/2026-01-27T14:16:39+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/mechanisms-associated-with-cardiovascular-risk-in-people-with-psoriasis/2026-01-27T14:16:55+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/cytokine-inhibitors-in-the-treatment-of-psoriasis/2026-01-27T14:17:17+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/use-of-cytokine-inhibitors-to-improve-cardiovascular-outcomes-in-people-with-psoriasis/2026-01-27T14:17:35+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/advice-for-dermatologists-on-effective-communication-with-cardiologists-in-the-setting-of-psoriasis/2026-01-27T14:18:04+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/advice-for-dermatologists/2026-01-27T14:18:14+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/are-pasi-scores-as-effective-for-diagnosis/2026-01-27T14:18:28+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/treatment-options-patients-with-localised-disease/2026-01-27T14:18:51+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/psoriasis-and-cardiovascular-disease/2026-01-27T14:19:02+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/background/2026-01-27T14:19:16+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/benefits-of-il-23p19-inhibition/2026-01-27T14:19:25+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/1FE147EA-B3ED-4724-8491EF7EFB2B9A66/2026-01-27T14:19:33+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/current-and-future-psoriasis-treatment/2026-01-27T14:19:45+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/unmet-needs-for-patients-with-psoriasis/2026-01-27T14:19:56+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/do-current-guidelines-provide-distinct-definitions/2026-01-27T14:20:09+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/do-we-have-good-safety-for-the-moderate-population/2026-01-27T14:20:19+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/efficacy/2026-01-27T14:20:28+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/33687E2D-6EC2-4BD0-A42C39506D8F4ECE/2026-01-27T14:20:39+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/introduction/2026-01-27T14:21:07+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/2D7E32A9-FC75-47DC-A465A0EB9157EF24/2026-01-27T14:21:16+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/mechanisms-of-increased-cvd-risk/2026-01-27T14:21:29+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/nehal-mehta-biography/2026-01-27T14:21:39+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/peter-van-de-kerkhof-biography/2026-01-27T14:21:49+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/96033E26-BABB-466B-B10658F0DE5B3416/2026-01-27T14:21:59+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/psoriasis-pathophysiology/2026-01-27T15:33:17+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/relevance-to-the-real-world/2026-01-27T14:22:20+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/targeting-cytokines/2026-01-27T14:22:28+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/tildrakizumab-3-year-data/2026-01-27T14:22:36+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/30E7DE6D-FD66-4FD8-BF9C9C34C8B5B219/2026-01-27T14:22:44+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/BEBF1536-D2FA-465D-970FE673CCCE2B3A/2026-01-27T14:22:55+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/what-is-your-top-tip-for-managing-psoriasis/2026-01-27T14:23:04+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/managing-patients-with-moderately-severe-disease/2026-01-27T14:23:12+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/patient-needs-systemic-therapy/2026-01-27T14:23:20+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-academy/guideline-updates-offer-guidance/2026-01-27T14:23:32+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-management/expert-videos-german/2026-01-27T14:12:01+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2019-videos/en-route-to-long-term-control/2026-01-27T14:14:02+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2019-videos/benefits-of-modern-biologic-treatment/2026-01-27T14:14:11+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2019-videos/targeting-safety-in-treatment-decisions/2026-01-27T14:15:18+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2019-videos/welcome-and-introductions/2026-01-27T14:15:30+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2019-videos/navigating-the-options-which-way-will-you-go/2026-01-27T14:14:26+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/faculty-discussion/secukinumab-case-study/2026-01-27T14:09:44+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/faculty-discussion/prevent-or-treat-nafld/2026-01-27T14:09:18+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/faculty-discussion/role-of-il-17-inhibition-in-the-future/2026-01-27T14:10:40+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/faculty-discussion/il-23p19-inhibitors-first-choice-biologics/2026-01-27T14:08:00+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/faculty-discussion/higher-risk-of-malignancy-with-il-23-inhibition/2026-01-27T14:08:45+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/faculty-discussion/tnf-inhibition/2026-01-27T14:09:30+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/faculty-discussion/treatment-with-a-tnf-inhibitor/2026-01-27T14:08:13+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/faculty-discussion/titrating-biologics-one-dose-available-advantage/2026-01-27T14:10:51+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/faculty-discussion/il-23p19-inhibitor-and-long-term-treatment/2026-01-27T14:09:55+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/faculty-discussion/screen-for-nafld-in-daily-practice/2026-01-27T14:07:41+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/why-is-tildrakizumab-the-drug-of-choice-for-treating-psoriasis-in-the-positive-study/2026-01-27T14:23:53+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/what-are-the-objectives-of-the-positive-study-on-psoriasis/2026-01-27T14:24:03+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/what-is-the-positive-study-and-why-is-it-needed-for-psoriasis-patients/2026-01-27T14:24:27+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/how-do-busy-practitioners-incorporate-wellbeing-surveys-during-psoriasis-consultations/2026-01-27T14:24:37+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/how-effective-is-cognitive-behavioural-therapy-cbt-as-part-of-psoriasis-treatment/2026-01-27T14:24:49+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/what-is-the-relationship-between-psoriasis-happiness-and-inflammation/2026-01-27T14:24:58+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/what-is-the-impact-of-psoriasis-on-happiness-and-wellbeing/2026-01-27T14:25:08+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/how-does-the-dlqi-match-up-with-wellbeing-and-pasi-in-psoriasis/2026-01-27T14:25:20+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/what-does-a-psychologist-say-about-pasi-90-and-pasi-100-from-a-wellbeing-perspective/2026-01-27T14:25:30+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/how-big-of-a-challenge-is-suicidal-ideation-in-psoriasis/2026-01-27T14:25:53+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/does-short-term-psoriasis-treatment-evidence-translate-into-improved-patient-wellbeing/2026-01-27T14:26:28+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/what-is-pasi100-in-real-life-clinical-practice-and-what-treatment-is-best-to-achieve-this/2026-01-27T14:26:38+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/what-is-the-pathogenic-process-of-psoriasis-and-how-does-stress-exacerbate-this/2026-01-27T14:26:46+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-academy/eadv-2021-videos/meet-professors-jordi-quoidbach-stefano-piaserico-and-ulrich-mrowietz/2026-01-27T14:26:55+00:00weekly0.6https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/ghd-expert-roundtable-old/growth-hormone-deficiency-steps-to-successful-treatment/2025-12-15T11:08:49+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/understanding-alopecia-areata/how-patients-with-alopecia-areata-value-their-hair/2025-12-18T11:00:00+00:00weekly0.6https://www.medthority.com/medical-education/alopecia-areata-learning-zone/understanding-alopecia-areata/addressing-unmet-needs-and-burden-of-disease-in-aa/2025-12-18T10:59:27+00:00weekly0.6https://www.medthority.com/medical-education/lipid-management-in-ascvd/publication-digest/the-santorini-study/2026-01-15T10:13:19+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/professor-rolland-gyulai2/2025-12-09T15:49:11+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/albumin-infusion-may-decrease-the-incidence-and-severity-of-overt-hepatic-encephalopathy-in-liver-cirrhosis/2026-01-13T13:29:20+00:00weekly0.6https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-kristin-highland-biography/2026-01-27T15:58:19+00:00weekly0.6https://www.medthority.com/medical-education/psoriasis-learning-zone/guidelines/getting-to-the-heart-of-comorbidities/2025-12-09T15:02:24+00:00weekly0.6https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/professor-elisabeth-bendstrup-biography/2026-01-27T15:58:14+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/serum-albumin-an-early-predictor/2026-01-13T11:25:34+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/long-term-albumin-administration/2026-01-13T11:27:40+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/harms-of-hes-evidence-to-date/2026-01-13T11:32:22+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/albumin-administration-and-cardiac-surgery/2026-01-13T11:43:42+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/swipe-randomised-clinical-trial/2026-01-13T11:40:59+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/long-term-administration-of-human-albumin/2026-01-13T11:41:57+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/extravascular-fluid-by-hyperoncotic-albumin/2026-01-13T11:46:30+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/albumin-administration-in-decompensated-cirrhosis/2026-01-13T11:47:51+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/fluid-therapy-for-major-abdominal-surgery/2026-01-13T11:52:45+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/albumin-use-in-decompensated-cirrhosis/2026-01-13T11:54:29+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/postoperative-renal-dysfunction/2026-01-13T11:56:35+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/saline-or-plasmalyte-as-crystalloid-fluid-therapy/2026-01-13T13:20:04+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/prehospital-hypertonic-saline/2026-01-13T13:21:00+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/hydroxyethyl-starch-solutions-and-patient-harm/2026-01-13T11:44:11+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/cmdh-endorses-prac-recommendation/2026-01-13T11:43:56+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/prac-recommends-against-hes/2026-01-13T11:43:30+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/intravenous-fluid-composition-on-outcomes/2026-01-13T11:39:54+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/aisf-simti-position-paper/2026-01-13T11:42:52+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/goals-directed-fluid-restriction/2026-01-13T11:45:22+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/albumin-treatment-regimen/2026-01-13T11:48:47+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/causal-relationship/2026-01-13T11:55:41+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/patterns-of-intravenous-fluid-resuscitation/2026-01-13T11:53:34+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/early-goal-directed-therapy-for-septic-shock/2026-01-13T11:57:28+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/perioperative-intravenous-fluid-prescribing/2026-01-13T13:18:38+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/fluid-management-in-sepsis/2026-01-13T13:23:01+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/goal-directed-fluid-therapy/2026-01-13T13:23:56+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/albumin-in-burn-shock-resuscitation/2026-01-13T11:29:39+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/albumin-postoperative-acute-kidney-injury/2026-01-13T13:25:04+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/management-of-complications-of-liver-cirrhosis/2026-01-13T13:25:57+00:00weekly0.6https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/fluid-resuscitation-in-sepsis/2026-01-13T13:28:21+00:00weekly0.6https://www.medthority.com/medical-education/managing-high-risk-nmibc/navigating-key-decisions-in-nmibc-care/2026-02-25T11:54:38+00:00weekly0.7https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/hrr-testing-key-clinical-considerations/2026-03-06T12:07:28+00:00weekly0.7https://www.medthority.com/medical-education/cidp-learning-zone/navigating-cidp-podcast-series/2026-03-11T14:14:41+00:00weekly0.7https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/expert-insights-into-aatd/2026-03-02T13:25:51+00:00weekly0.7https://www.medthority.com/medical-education/webinar-accredited-aa-in-skin-of-color-populations/transcript-alopecia-areata-in-skin-of-color-patients/2026-03-19T10:28:54+00:00weekly0.7https://www.medthority.com/medical-education/webinar-accredited-aa-in-skin-of-color-populations/assessment/2026-03-19T08:58:06+00:00weekly0.7https://www.medthority.com/medical-education/ifn-gamma-in-hyperinflammation/acr-2025-biomarker-advances-in-hlhmas/2025-12-18T15:57:06+00:00weekly0.7https://www.medthority.com/medical-education/desmoid-tumors-insights-from-dgho-2025/transcript-surgical-management-of-desmoid-tumors/2025-11-12T11:45:30+00:00weekly0.7https://www.medthority.com/medical-education/desmoid-tumors-insights-from-dgho-2025/transcript-desmoid-tumors-treatment-landscape/2025-11-12T11:45:20+00:00weekly0.7https://www.medthority.com/medical-education/desmoid-tumors-insights-from-dgho-2025/transcript-desmoid-tumors-patient-perspective/2025-11-12T11:45:01+00:00weekly0.7https://www.medthority.com/medical-education/desmoid-tumors-insights-from-dgho-2025/transcript-diagnostic-assessment-of-desmoid-tumors/2025-11-12T11:44:31+00:00weekly0.7https://www.medthority.com/medical-education/alopecia-areata-learning-zone/podcast-alopecia-areata-in-conversation/2025-12-22T09:19:30+00:00weekly0.7https://www.medthority.com/medical-education/esmo-congress-2025/keynote-905-a-practice-changing-trial/2025-11-26T13:48:35+00:00weekly0.7https://www.medthority.com/medical-education/think-thrombosis/roundtable-insights-from-2025/2025-12-19T09:30:51+00:00weekly0.7https://www.medthority.com/medical-education/webinar-aa-in-skin-of-color-populations/assessment/2025-12-02T09:58:17+00:00weekly0.7https://www.medthority.com/medical-education/webinar-aa-in-skin-of-color-populations/transcript-alopecia-areata-in-skin-of-color-patients/2025-12-10T08:34:18+00:00weekly0.7https://www.medthority.com/medical-education/eano-2025-nf1-expert-insights/transcript-multi-parametric-biomarkers-in-nf1/2025-12-22T11:41:11+00:00weekly0.7https://www.medthority.com/medical-education/esmo-congress-2025/bladder-cancer-antibodydrug-conjugates/2025-11-28T10:58:28+00:00weekly0.7https://www.medthority.com/medical-education/eadv-2025/eadv-2025-hidradenitis-suppurativa-highlights/2025-10-03T12:50:31+00:00weekly0.7https://www.medthority.com/medical-education/eadv-2025/eadv-2025-alopecia-areata-highlights/2025-10-03T12:50:03+00:00weekly0.7https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/overcoming-barriers-to-hrr-testing/2026-02-19T12:54:26+00:00weekly0.7https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/aatd-liver-care-easl-2025-summary/2026-01-26T12:51:31+00:00weekly0.7https://www.medthority.com/medical-education/eadv-2025/eadv-congress-2025/2025-10-06T12:40:04+00:00weekly0.7https://www.medthority.com/medical-education/eano-2025-nf1-expert-insights/transcript-unmet-needs-for-people-living-with-nf1/2025-10-31T15:05:16+00:00weekly0.7https://www.medthority.com/medical-education/eano-2025-nf1-expert-insights/transcript-key-data-and-insights-from-reneu-trial/2025-10-31T15:05:49+00:00weekly0.7https://www.medthority.com/medical-education/wclc-2025/phase-3-data-shift-nsclc-landscape/2025-09-15T13:33:30+00:00weekly0.7https://www.medthority.com/medical-education/wclc-2025/lung-cancer-imaging-and-challenging-cases/2025-09-15T13:33:44+00:00weekly0.7https://www.medthority.com/medical-education/wclc-2025/key-data-oncogene-driven-nsclc/2025-09-15T13:33:16+00:00weekly0.7https://www.medthority.com/medical-education/wclc-2025/world-conference-on-lung-cancer-2025/2025-09-16T12:18:33+00:00weekly0.7https://www.medthority.com/medical-education/ifn-gamma-in-hyperinflammation/secondary-hlhmas-masterclass/2026-01-20T09:41:55+00:00weekly0.7https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/podcast-expert-exchanges-hrr-in-mpc/2026-02-17T11:14:10+00:00weekly0.7https://www.medthority.com/medical-education/think-thrombosis/esc-2025-advances-in-understanding/2025-12-19T09:39:50+00:00weekly0.7https://www.medthority.com/medical-education/managing-high-risk-nmibc/asco-2025-expert-reflections/2026-01-27T15:48:05+00:00weekly0.7https://www.medthority.com/medical-education/think-thrombosis/thrombosis-focus-congress-updates/2025-12-19T09:33:35+00:00weekly0.7https://www.medthority.com/medical-education/think-thrombosis/isth2025-thrombosis-advances/2025-12-19T09:37:11+00:00weekly0.7https://www.medthority.com/medical-education/ifn-gamma-in-hyperinflammation/unveiling-hlhmas/2025-12-18T15:57:30+00:00weekly0.7https://www.medthority.com/medical-education/ifn-gamma-in-hyperinflammation/meet-the-experts/2025-12-18T15:58:13+00:00weekly0.7https://www.medthority.com/medical-education/accredited-whats-new-in-tk2d2/transcript-tk2d-symposium-at-epns-congress-2025/2026-01-26T11:03:08+00:00weekly0.7https://www.medthority.com/medical-education/managing-high-risk-nmibc/video-transcripts/2026-01-27T15:47:56+00:00weekly0.7https://www.medthority.com/medical-education/alopecia-areata-learning-zone/alopecia-areata-management-update/2025-12-18T10:24:12+00:00weekly0.7https://www.medthority.com/medical-education/alopecia-areata-learning-zone/understanding-alopecia-areata/2025-12-18T10:55:26+00:00weekly0.7https://www.medthority.com/medical-education/alopecia-areata-learning-zone/the-future-of-alopecia-areata/2025-12-18T10:25:48+00:00weekly0.7https://www.medthority.com/medical-education/managing-high-risk-nmibc/podcast-expert-voices/2026-02-25T11:56:53+00:00weekly0.7https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/optimizing-csu-care/2026-01-12T14:51:05+00:00weekly0.7https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/why-early-aatd-diagnosis-is-key-to-optimal-liver-disease-management/2026-01-26T12:51:20+00:00weekly0.7https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/accredited-aatd-liver-care-journey/2026-01-26T12:50:46+00:00weekly0.7https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/meet-the-experts/2026-01-12T14:55:23+00:00weekly0.7https://www.medthority.com/medical-education/alopecia-areata-learning-zone/alopecia-areata-congress-coverage/2025-12-18T11:02:40+00:00weekly0.7https://www.medthority.com/medical-education/alopecia-areata-learning-zone/meet-the-experts/2025-12-18T11:05:07+00:00weekly0.7https://www.medthority.com/medical-education/alopecia-areata-learning-zone/alopecia-areata-management-and-unmet-needs/2026-01-09T10:18:27+00:00weekly0.7https://www.medthority.com/medical-education/ifn-gamma-in-hyperinflammation/clinical-guide-to-hlhmas/2025-12-18T15:56:40+00:00weekly0.7https://www.medthority.com/medical-education/ifn-gamma-in-hyperinflammation/learning-zone-feedback/2026-01-27T16:12:33+00:00weekly0.7https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/csu-congress-updates/2026-01-12T14:54:00+00:00weekly0.7https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/progress-in-hrr-testing-for-prostate-cancer/2025-12-15T11:02:08+00:00weekly0.7https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/learning-zone-feedback/2026-01-27T16:00:39+00:00weekly0.7https://www.medthority.com/medical-education/accredited-symposium-elevating-lopd-care/transcript-accredited-lopd-symposium/2026-02-24T11:29:18+00:00weekly0.7https://www.medthority.com/medical-education/alopecia/alopecia-areata-current-and-emerging-therapies/2026-03-16T11:48:50+00:00weekly0.7https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/congress-highlights-2025/2026-03-06T11:52:02+00:00weekly0.7https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/congress-highlights/2025-12-15T10:13:57+00:00weekly0.7https://www.medthority.com/medical-education/alopecia/the-psychosocial-impacts-of-aa-more-than-hair-loss/2026-03-16T11:49:20+00:00weekly0.7https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/learning-zone-feedback/2026-01-26T11:17:44+00:00weekly0.7https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/managing-csu/2026-01-12T14:54:56+00:00weekly0.7https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/csu-resources/2026-01-12T14:54:30+00:00weekly0.7https://www.medthority.com/medical-education/complement-mediated-kidney-diseases-learning-zone/cmkds-podcast-series/2026-01-16T10:20:34+00:00weekly0.7https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/mcrpc-challenges-and-treatments/2025-12-11T14:10:14+00:00weekly0.7https://www.medthority.com/medical-education/mg-at-ean-2024/real-world-data/2025-08-04T14:03:21+00:00weekly0.7https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/roundtable-mcrpc-update-2024/2025-12-11T14:09:28+00:00weekly0.7https://www.medthority.com/medical-education/mg-at-ean-2024/individualised-treatment-for-mg/2025-08-04T14:01:20+00:00weekly0.7https://www.medthority.com/medical-education/mg-at-ean-2024/gender-medicine-and-mg/2025-08-04T14:02:47+00:00weekly0.7https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/expert-opinions-on-mcrpc-management/2025-12-11T14:10:51+00:00weekly0.7https://www.medthority.com/medical-education/think-thrombosis/esc-2024/2025-12-19T09:46:54+00:00weekly0.7https://www.medthority.com/medical-education/vms-hub/vms-menopause-and-management/2025-10-15T12:56:51+00:00weekly0.7https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/eadv-2024/2026-01-14T08:21:31+00:00weekly0.7https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/ebac-accredited-lymphoma-roundtable/2026-03-11T08:41:01+00:00weekly0.7https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/transforming-outcomes-for-people-with-gmg/2026-01-27T15:33:41+00:00weekly0.7https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/surgery-for-hs/2025-12-16T14:53:06+00:00weekly0.7https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/pathophysiology/2025-12-16T14:53:55+00:00weekly0.7https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/optimising-hs-management/2025-12-16T14:52:36+00:00weekly0.7https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/medications-for-hs/2025-12-16T14:52:07+00:00weekly0.7https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/podcast-series-navigating-al-amyloidosis/2026-02-16T12:54:56+00:00weekly0.7https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/esc-2023-highlights-article-1/2026-02-16T12:59:24+00:00weekly0.7https://www.medthority.com/medical-education/cidp-learning-zone/cidp-demystified-from-diagnosis-to-management/2025-12-16T15:58:26+00:00weekly0.7https://www.medthority.com/medical-education/cidp-learning-zone/learning-zone-feedback/2026-01-27T16:09:54+00:00weekly0.7https://www.medthority.com/medical-education/alopecia/what-works-best-for-your-patient/2026-03-16T11:48:20+00:00weekly0.7https://www.medthority.com/medical-education/alopecia/inclusive-care-in-alopecia-beyond-diagnosis/2026-03-16T11:46:08+00:00weekly0.7https://www.medthority.com/medical-education/alopecia/assessing-severity-in-skin-of-color-patients/2026-03-16T11:47:15+00:00weekly0.7https://www.medthority.com/medical-education/managing-high-risk-nmibc/advances-in-diagnosis-and-management/2025-12-19T09:50:31+00:00weekly0.7https://www.medthority.com/medical-education/managing-high-risk-nmibc/learning-zone-feedback/2026-01-27T15:47:46+00:00weekly0.7https://www.medthority.com/medical-education/managing-high-risk-nmibc/expert-and-patient-insights/2025-12-16T15:25:03+00:00weekly0.7https://www.medthority.com/medical-education/managing-high-risk-nmibc/congress-highlights-nmibc/2026-03-03T10:35:14+00:00weekly0.7https://www.medthority.com/medical-education/ulcerative-colitis/ulcerative-colitis-treatment/2025-12-02T14:21:00+00:00weekly0.7https://www.medthority.com/medical-education/ulcerative-colitis/ulcerative-colitis-overview/2025-12-02T14:20:10+00:00weekly0.7https://www.medthority.com/medical-education/ulcerative-colitis/learning-zone-feedback/2026-01-27T14:41:15+00:00weekly0.7https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/isa-2022-highlights-article-1/2026-02-09T10:05:10+00:00weekly0.7https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/isa-2022-highlights-article-2/2026-02-09T10:07:04+00:00weekly0.7https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/isa-2022-highlights-article-3/2026-02-09T10:07:22+00:00weekly0.7https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/esc-2023-highlights-article-2/2026-02-09T10:02:57+00:00weekly0.7https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/al-amyloidosis-interactive-patient-journey/2026-02-16T12:47:30+00:00weekly0.7https://www.medthority.com/medical-education/lipid-management-in-ascvd/lipid-management-at-esc-2023-congress-highlights/2026-01-15T09:29:32+00:00weekly0.7https://www.medthority.com/medical-education/anti-cgrps-therapies-for-migraine/anti-cgrp-advances-in-migraine-treatment/2025-12-15T11:54:30+00:00weekly0.7https://www.medthority.com/medical-education/ulcerative-colitis/treatment-decision-making-for-ulcerative-colitis/2025-12-02T14:21:49+00:00weekly0.7https://www.medthority.com/medical-education/ulcerative-colitis/expert-opinion-on-ulcerative-colitis/2025-12-02T14:22:23+00:00weekly0.7https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/eadv-2023/2026-01-14T09:34:53+00:00weekly0.7https://www.medthority.com/medical-education/lead-from-the-frontline-optimizing-first-line-treatment-selection-in-ph-all/5-minutes-on-the-leukemia-landscape-with-dr-elias-jabbour/2026-01-27T15:33:25+00:00weekly0.7https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/podcast-series-whats-new-in-mcrpc/2026-01-22T11:18:30+00:00weekly0.7https://www.medthority.com/medical-education/complement-mediated-kidney-diseases-learning-zone/asn-2023-iga-nephropathy-and-other-cmkds/2026-01-16T10:18:08+00:00weekly0.7https://www.medthority.com/medical-education/ulcerative-colitis/roundtable-uc-at-uegw-2023/2025-12-02T14:19:31+00:00weekly0.7https://www.medthority.com/medical-education/lipid-management-in-ascvd/lipid-lowering-landscape-advances-in-ascvd-from-2023/2026-01-15T09:29:01+00:00weekly0.7https://www.medthority.com/medical-education/pompe-disease-key-findings-from-wms-2022/wms-podcast-series/2026-01-27T15:22:35+00:00weekly0.7https://www.medthority.com/medical-education/food-allergy/eaaci-2023-food-allergy-symposium/2025-12-18T15:08:17+00:00weekly0.7https://www.medthority.com/medical-education/complement-mediated-kidney-diseases-learning-zone/complement-in-kidney-disease/2026-01-16T10:18:38+00:00weekly0.7https://www.medthority.com/medical-education/complement-mediated-kidney-diseases-learning-zone/c3-glomerulopathy-c3g/2026-01-16T10:19:10+00:00weekly0.7https://www.medthority.com/medical-education/complement-mediated-kidney-diseases-learning-zone/iga-nephropathy-igan/2026-01-16T10:19:47+00:00weekly0.7https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/unmet-needs-in-myasthenia-gravis/2025-12-11T10:10:58+00:00weekly0.7https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/learning-zone-feedback/2026-01-27T15:33:33+00:00weekly0.7https://www.medthority.com/medical-education/alopecia-areata-learning-zone/wcd-2023-congress-highlights/2025-12-18T11:10:13+00:00weekly0.7https://www.medthority.com/medical-education/weight-control-in-diabetes/congress-highlights/2025-12-02T13:16:22+00:00weekly0.7https://www.medthority.com/medical-education/lipid-management-in-ascvd/eas-2023/2026-01-15T09:58:52+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-academy/the-academy/2026-01-27T14:01:38+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-academy/people-centred-care-in-psoriasis/2025-12-09T09:56:42+00:00weekly0.7https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/learning-zone-feedback/2026-01-27T15:35:42+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-management/2026-01-27T14:11:23+00:00weekly0.7https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/unlocking-myasthenia-gravis/2026-03-09T11:42:15+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-guidelines/2025-12-09T10:01:29+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-academy/feedback/2026-01-27T14:13:30+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-academy/psoriasis-treatment/2026-01-27T14:12:21+00:00weekly0.7https://www.medthority.com/medical-education/alopecia-areata-learning-zone/alopecia-areata-awareness-podcast-series/2025-12-18T11:02:01+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-academy/key-evidence-on-psoriasis-treatments/2025-12-09T10:00:59+00:00weekly0.7https://www.medthority.com/medical-education/complement-mediated-kidney-diseases-learning-zone/publication-digests/2026-01-16T10:25:16+00:00weekly0.7https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/discussing-myasthenia-gravis-with-professor-heinz-wiendl/2025-12-11T10:13:06+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-academy/expert-opinion--patient-wellbeing-in-psoriasis/2025-12-09T10:02:20+00:00weekly0.7https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/growth-hormone-deficiency/2025-12-15T11:13:27+00:00weekly0.7https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/ghd-treatment-landscape/2025-12-15T11:12:57+00:00weekly0.7https://www.medthority.com/medical-education/anti-cgrps-therapies-for-migraine/learning-zone-feedback/2026-01-26T11:16:35+00:00weekly0.7https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/learning-zone-feedback/2026-03-12T11:09:07+00:00weekly0.7https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/hs-publication-explainers/2025-12-16T14:49:25+00:00weekly0.7https://www.medthority.com/medical-education/anti-cgrps-therapies-for-migraine/anti-cgrps-in-migraine/2025-12-15T11:49:46+00:00weekly0.7https://www.medthority.com/medical-education/anti-cgrps-therapies-for-migraine/migraine-overview/2025-12-15T11:39:15+00:00weekly0.7https://www.medthority.com/medical-education/st-gallens-2023-highlights/st.-gallen-international-breast-cancer-conference-20232025-10-16T11:11:53+00:00weekly0.7https://www.medthority.com/medical-education/st-gallens-2023-highlights/st.-gallen-international-breast-cancer-conference-2023-day-22025-10-16T11:12:44+00:00weekly0.7https://www.medthority.com/medical-education/st-gallens-2023-highlights/st.-gallen-international-breast-cancer-conference-2023-day-32025-10-16T11:13:24+00:00weekly0.7https://www.medthority.com/medical-education/alopecia-areata-learning-zone/alopecia-areata-highlights-from-aad-2023/2025-12-18T11:03:11+00:00weekly0.7https://www.medthority.com/medical-education/vms-hub/introducing-vms/2025-10-15T12:51:50+00:00weekly0.7https://www.medthority.com/medical-education/vms-hub/advances-in-vasomotor-symptom-treatments/2025-10-15T12:56:36+00:00weekly0.7https://www.medthority.com/medical-education/vms-hub/oestradiol-withdrawal-in-the-pathophysiology-of-vms/2025-10-15T12:56:11+00:00weekly0.7https://www.medthority.com/medical-education/vms-hub/mental-health-implications-of-vms/2025-10-15T12:55:13+00:00weekly0.7https://www.medthority.com/medical-education/vms-hub/understanding-the-burden-of-vms-on-womens-lives/2025-10-15T12:54:57+00:00weekly0.7https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/ehsf-2024/2025-12-16T14:37:05+00:00weekly0.7https://www.medthority.com/medical-education/lipid-management-in-ascvd/meet-the-experts/2026-01-15T11:24:29+00:00weekly0.7https://www.medthority.com/medical-education/think-thrombosis/atrial-fibrillation-and-stroke-prevention/2025-12-19T09:34:20+00:00weekly0.7https://www.medthority.com/medical-education/think-thrombosis/venous-thromboembolism/2025-12-19T09:36:02+00:00weekly0.7https://www.medthority.com/medical-education/think-thrombosis/isth2024-thrombosis-advances/2025-12-19T09:47:37+00:00weekly0.7https://www.medthority.com/medical-education/think-thrombosis/podcasts/2025-12-19T09:32:48+00:00weekly0.7https://www.medthority.com/medical-education/think-thrombosis/expert-opinion/2025-12-19T09:48:19+00:00weekly0.7https://www.medthority.com/medical-education/think-thrombosis/learning-zone-feedback/2026-01-27T16:07:55+00:00weekly0.7https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/hs-guidelines/2025-12-16T14:38:44+00:00weekly0.7https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/ghd-expert-roundtable/2026-03-12T11:03:24+00:00weekly0.7https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/patient-focused-case-studies/2025-12-11T10:11:20+00:00weekly0.7https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/learning-zone-feedback/2026-01-27T16:02:58+00:00weekly0.7https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/learning-zone-feedback/2026-03-12T12:32:13+00:00weekly0.7https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/asco-2024/2026-03-12T12:29:01+00:00weekly0.7https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/ash-2024/2026-03-12T12:25:08+00:00weekly0.7https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/esmo-2024/2026-03-12T12:25:51+00:00weekly0.7https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/eha2024-highlights/2026-03-12T12:30:04+00:00weekly0.7https://www.medthority.com/medical-education/alopecia-areata-learning-zone/highlights-from-aad-2024/2025-12-18T10:27:56+00:00weekly0.7https://www.medthority.com/medical-education/modern-management-rrmm/hot-topics-in-rrmm/2025-12-09T14:30:59+00:00weekly0.7https://www.medthority.com/medical-education/future-breast-cancer-2024/eleanor-impassion132-targeted-combination-for-mbc/2025-10-13T09:38:29+00:00weekly0.7https://www.medthority.com/medical-education/future-breast-cancer-2024/federica-and-morpheus-panbc/2025-10-13T09:38:45+00:00weekly0.7https://www.medthority.com/medical-education/future-breast-cancer-2024/tropion-breast01-decision-support-with-her2dx/2025-10-13T09:39:00+00:00weekly0.7https://www.medthority.com/medical-education/future-breast-cancer-2024/exemestane-in-tamoxifen-resistance-and-head-to-head-with-letrozole/2025-10-13T09:39:14+00:00weekly0.7https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/current-state-of-lymphoma-care/2025-12-18T09:22:55+00:00weekly0.7https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/living-with-mg-a-patient-perspective/2025-12-11T10:12:44+00:00weekly0.7https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/congress-highlights/2025-12-11T14:15:39+00:00weekly0.7https://www.medthority.com/medical-education/lipid-management-in-ascvd/publication-digest/2026-01-15T10:06:49+00:00weekly0.7https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/thank-you-for-your-participation/2026-01-27T15:34:35+00:00weekly0.7https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/thank-you-for-completing-the-questionnaire/2026-01-27T15:35:09+00:00weekly0.7https://www.medthority.com/medical-education/complement-mediated-kidney-diseases-learning-zone/congress-highlights/2026-01-16T10:21:07+00:00weekly0.7https://www.medthority.com/medical-education/sabcs-highlights-2022/parp-inhibitors-and-resistance-mechanisms/2026-01-21T08:53:47+00:00weekly0.7https://www.medthority.com/medical-education/sabcs-highlights-2022/phase-iii-trial-updates-and-a-her2-low-debate/2026-01-21T08:52:54+00:00weekly0.7https://www.medthority.com/medical-education/sabcs-highlights-2022/new-developments-in-hrher2-therapy/2026-01-21T08:55:43+00:00weekly0.7https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/the-future-of-immunology-biosimilars/2026-01-19T10:52:17+00:00weekly0.7https://www.medthority.com/medical-education/pompe-disease-key-findings-from-wms-2022/accredited-roundtable/2026-01-27T15:21:55+00:00weekly0.7https://www.medthority.com/medical-education/weight-control-in-diabetes/type-2-diabetes/2025-12-02T13:15:11+00:00weekly0.7https://www.medthority.com/medical-education/weight-control-in-diabetes/weight-management-in-t2d/2025-12-02T13:15:44+00:00weekly0.7https://www.medthority.com/medical-education/weight-control-in-diabetes/thank-you-for-taking-our-short-feedback-survey/2026-01-27T14:40:56+00:00weekly0.7https://www.medthority.com/medical-education/weight-control-in-diabetes/thank-you-for-completing-our-short-feedback-survey/2026-01-27T14:41:02+00:00weekly0.7https://www.medthority.com/medical-education/respiratory-syncytial-virus/ers-2022-congress-highlights/2025-12-02T14:37:21+00:00weekly0.7https://www.medthority.com/medical-education/lipid-management-in-ascvd/expert-opinion/2026-01-15T10:16:41+00:00weekly0.7https://www.medthority.com/medical-education/pompe-disease-key-findings-from-wms-2022/congress-highlights/2026-01-27T15:19:59+00:00weekly0.7https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/webinar-highlights-2022/2026-01-27T15:31:56+00:00weekly0.7https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/congress-highlights/2025-12-08T08:58:50+00:00weekly0.7https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/congress-highlights/2026-01-19T10:55:39+00:00weekly0.7https://www.medthority.com/medical-education/food-allergy/congress/2025-12-19T08:56:31+00:00weekly0.7https://www.medthority.com/medical-education/asco-2022-symposium-highlights/day-two-highlights-later-line-breast-and-precision-colon-cancer-treatments/2025-06-23T09:15:38+00:00weekly0.7https://www.medthority.com/medical-education/asco-2022-symposium-highlights/day-three-highlights-exciting-results-from-the-destiny-paradigm-and-reecur-trials/2025-06-23T09:16:22+00:00weekly0.7https://www.medthority.com/medical-education/asco-2022-symposium-highlights/day-four--five-highlights-novel-developments-in-breast-ovarian-and-prostate-cancer/2025-06-23T09:17:07+00:00weekly0.7https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/biosimilars-in-retinal-disease/2025-12-18T13:46:33+00:00weekly0.7https://www.medthority.com/medical-education/asco-2022-symposium-highlights/highlights-from-asco-2022/2025-06-23T09:14:17+00:00weekly0.7https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/fast-facts/2026-01-05T12:49:36+00:00weekly0.7https://www.medthority.com/medical-education/respiratory-syncytial-virus/congress-highlights/2025-12-02T14:35:36+00:00weekly0.7https://www.medthority.com/medical-education/respiratory-syncytial-virus/wonca-2022-congress-highlights/2026-01-21T13:03:43+00:00weekly0.7https://www.medthority.com/medical-education/lupus-learning-zone/congress-highlights/2025-12-15T09:34:57+00:00weekly0.7https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/patient-focus-case-studies/2025-12-05T09:49:18+00:00weekly0.7https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/publication-digest/2026-01-13T09:55:47+00:00weekly0.7https://www.medthority.com/medical-education/supportive-care-in-oncology/supportive-care-options-for-cancer/2026-01-19T13:55:20+00:00weekly0.7https://www.medthority.com/medical-education/supportive-care-in-oncology/thank-you-for-taking-our-short-feedback-survey/2026-01-19T14:23:33+00:00weekly0.7https://www.medthority.com/medical-education/supportive-care-in-oncology/thank-you-for-your-time/2026-01-19T14:28:45+00:00weekly0.7https://www.medthority.com/medical-education/supportive-care-in-oncology/supportive-care-in-cancer/2026-01-19T13:49:21+00:00weekly0.7https://www.medthority.com/medical-education/supportive-care-in-oncology/quick-quiz/2026-01-19T14:00:28+00:00weekly0.7https://www.medthority.com/medical-education/lipid-management-in-ascvd/lipids-in-ascvd/2026-01-15T10:14:26+00:00weekly0.7https://www.medthority.com/medical-education/lipid-management-in-ascvd/treating-lipid-disorders/2026-01-15T10:15:33+00:00weekly0.7https://www.medthority.com/medical-education/supportive-care-in-oncology/expert-opinion/2026-01-19T14:05:32+00:00weekly0.7https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/esc-2022-highlights/2026-01-27T12:10:32+00:00weekly0.7https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/congress-highlights/2026-01-16T09:37:19+00:00weekly0.7https://www.medthority.com/medical-education/esmo-2022-symposium/expert-wrap-up-interview/2025-10-13T10:22:16+00:00weekly0.7https://www.medthority.com/medical-education/glaucoma-learning-zone/glaucoma-overview/2025-12-05T09:39:20+00:00weekly0.7https://www.medthority.com/medical-education/glaucoma-learning-zone/diagnosing-glaucoma/2025-12-05T09:39:47+00:00weekly0.7https://www.medthority.com/medical-education/glaucoma-learning-zone/treating-glaucoma/2025-12-05T09:40:16+00:00weekly0.7https://www.medthority.com/medical-education/glaucoma-learning-zone/publication-digests/2025-12-05T09:40:59+00:00weekly0.7https://www.medthority.com/medical-education/atopic-derm/aad-2022/2025-12-16T13:48:26+00:00weekly0.7https://www.medthority.com/medical-education/major-depressive-disorder-treatment-resistant-depression/major-depressive-disorder-mdd/2025-12-11T10:52:48+00:00weekly0.7https://www.medthority.com/medical-education/major-depressive-disorder-treatment-resistant-depression/biology-of-trd/2025-12-11T10:53:24+00:00weekly0.7https://www.medthority.com/medical-education/major-depressive-disorder-treatment-resistant-depression/treating-trd/2025-12-11T10:54:10+00:00weekly0.7https://www.medthority.com/medical-education/atopic-derm/publication-digests/2025-12-16T13:52:16+00:00weekly0.7https://www.medthority.com/medical-education/esmo-2022-symposium/esmo-breast-cancer-2022-day-3/2025-10-13T10:22:01+00:00weekly0.7https://www.medthority.com/medical-education/esmo-2022-symposium/esmo-breast-cancer-2022-congress-highlights/2025-10-16T11:07:48+00:00weekly0.7https://www.medthority.com/medical-education/esmo-2022-symposium/esmo-breast-cancer-2022-day-2/2025-10-13T10:21:43+00:00weekly0.7https://www.medthority.com/medical-education/respiratory-syncytial-virus/eccmid-2022-congress-highlights/2026-01-21T13:02:36+00:00weekly0.7https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/acs-patient-focus/2026-01-27T11:52:42+00:00weekly0.7https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/expert-opinion/2026-01-27T11:53:01+00:00weekly0.7https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/breast-cancer/2026-01-13T09:26:33+00:00weekly0.7https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/cdk46-inhibitors-in-advanced-breast-cancer/2026-01-13T09:27:13+00:00weekly0.7https://www.medthority.com/medical-education/improving-treatment-options-childhood-psoriasis/espd-virtual-2021/2026-01-13T08:38:45+00:00weekly0.7https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/how-to-deliver-vba/2025-12-02T14:06:58+00:00weekly0.7https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/congress-highlights/2026-01-13T09:56:35+00:00weekly0.7https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/expert-opinion/2026-01-19T10:32:43+00:00weekly0.7https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/key-learning/2025-12-15T10:06:27+00:00weekly0.7https://www.medthority.com/medical-education/osteoarthritis-associated-pain/congress-updates/2025-12-11T15:13:49+00:00weekly0.7https://www.medthority.com/medical-education/cancer-associated-thrombosis-learning-zone/vte-risk-in-cancer/2026-01-19T11:28:11+00:00weekly0.7https://www.medthority.com/medical-education/cancer-associated-thrombosis-learning-zone/cancer-associated-vte-guidelines/2026-01-19T11:31:06+00:00weekly0.7https://www.medthority.com/medical-education/cancer-associated-thrombosis-learning-zone/doac-treatments-for-cat/2026-01-19T11:33:49+00:00weekly0.7https://www.medthority.com/medical-education/cancer-associated-thrombosis-learning-zone/congresses/2026-01-19T11:34:26+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-learning-zone/bad-highlights/2025-12-09T15:50:37+00:00weekly0.7https://www.medthority.com/medical-education/improving-treatment-options-childhood-psoriasis/eadv-2020/2026-01-13T08:39:33+00:00weekly0.7https://www.medthority.com/medical-education/improving-treatment-options-childhood-psoriasis/meet-the-experts/2026-01-13T08:40:15+00:00weekly0.7https://www.medthority.com/medical-education/improving-treatment-options-childhood-psoriasis/whats-wrong-with-mia/2026-01-13T08:30:32+00:00weekly0.7https://www.medthority.com/medical-education/improving-treatment-options-childhood-psoriasis/mias-treatment/2026-01-13T08:31:09+00:00weekly0.7https://www.medthority.com/medical-education/improving-treatment-options-childhood-psoriasis/is-the-future-clear-for-mia-and-her-skin/2026-01-13T08:32:03+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-learning-zone/featured-educational-video/2025-12-09T15:49:52+00:00weekly0.7https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/cdk46-inhibitor-selection/2026-01-13T09:27:54+00:00weekly0.7https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/expert-opinion/2026-01-13T09:29:16+00:00weekly0.7https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/delivering-effective-very-brief-advice2/2025-12-02T14:07:34+00:00weekly0.7https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/what-is-very-brief-advice/2025-12-02T14:04:59+00:00weekly0.7https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/treating-tobacco-dependency/2025-12-02T14:06:38+00:00weekly0.7https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/expert-opinion/2025-12-02T14:11:12+00:00weekly0.7https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/ipcrg-meet-the-faculty/2025-12-02T14:13:26+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-learning-zone/covid-19-in-context/2025-12-09T15:06:19+00:00weekly0.7https://www.medthority.com/medical-education/osteoarthritis-associated-pain/expert-opinion/2025-12-11T15:13:25+00:00weekly0.7https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/featured-educational-video/2025-12-02T14:13:47+00:00weekly0.7https://www.medthority.com/medical-education/dna-repair-in-prostate-cancer-learning-zone/prostate-cancer/2025-12-15T11:30:00+00:00weekly0.7https://www.medthority.com/medical-education/dna-repair-in-prostate-cancer-learning-zone/dna-repair/2025-12-15T11:30:29+00:00weekly0.7https://www.medthority.com/medical-education/dna-repair-in-prostate-cancer-learning-zone/molecular-diagnostics/2025-12-15T11:31:00+00:00weekly0.7https://www.medthority.com/medical-education/dna-repair-in-prostate-cancer-learning-zone/lexicon/2025-12-15T11:31:22+00:00weekly0.7https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/publication-digest/2026-01-16T10:09:40+00:00weekly0.7https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/publication-digest/2026-01-27T09:22:31+00:00weekly0.7https://www.medthority.com/medical-education/respiratory-syncytial-virus/rsv-burden/2025-12-02T14:33:15+00:00weekly0.7https://www.medthority.com/medical-education/respiratory-syncytial-virus/diagnosing-rsv/2025-12-02T14:32:41+00:00weekly0.7https://www.medthority.com/medical-education/respiratory-syncytial-virus/managing-rsv/2025-12-02T14:34:56+00:00weekly0.7https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/expert-opinion/2026-01-27T09:02:38+00:00weekly0.7https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/chronic-kidney-disease/2026-01-16T09:56:01+00:00weekly0.7https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/diagnosing-chronic-kidney-disease/2026-01-16T09:56:38+00:00weekly0.7https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/treating-chronic-kidney-disease/2026-01-16T09:57:14+00:00weekly0.7https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/patient-stratification/2025-12-11T11:05:03+00:00weekly0.7https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/molecular-testing/2025-12-11T11:06:34+00:00weekly0.7https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/ret-inhibitors/2025-12-11T11:04:15+00:00weekly0.7https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/hs-overview/2025-12-16T14:37:54+00:00weekly0.7https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/hs-treatment/2025-12-16T14:38:19+00:00weekly0.7https://www.medthority.com/medical-education/lupus-learning-zone/publication-digests/2025-12-15T09:37:44+00:00weekly0.7https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/expert-opinion/2026-01-14T10:08:45+00:00weekly0.7https://www.medthority.com/medical-education/lupus-learning-zone/lupus-webinar/2025-12-15T09:37:24+00:00weekly0.7https://www.medthority.com/medical-education/improving-treatment-options-childhood-psoriasis/eadv-virtual-2021/2026-01-13T08:35:42+00:00weekly0.7https://www.medthority.com/medical-education/food-allergy/food-allergy/2025-12-18T15:08:46+00:00weekly0.7https://www.medthority.com/medical-education/food-allergy/diagnosing-food-allergy/2025-12-18T15:12:35+00:00weekly0.7https://www.medthority.com/medical-education/food-allergy/treating-food-allergy/2025-12-18T15:13:08+00:00weekly0.7https://www.medthority.com/medical-education/food-allergy/future-of-food-allergy/2025-12-18T15:19:34+00:00weekly0.7https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/understanding-ms/2025-12-08T08:39:18+00:00weekly0.7https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/meet-the-experts/2025-12-05T09:49:57+00:00weekly0.7https://www.medthority.com/medical-education/lupus-learning-zone/meet-the-experts/2025-12-15T09:38:14+00:00weekly0.7https://www.medthority.com/medical-education/atopic-derm/atopic-dermatitis-overview/2025-12-16T13:46:42+00:00weekly0.7https://www.medthority.com/medical-education/atopic-derm/atopic-dermatitis-treatment/2025-12-16T13:47:08+00:00weekly0.7https://www.medthority.com/medical-education/atopic-derm/expert-opinion/2025-12-16T13:47:34+00:00weekly0.7https://www.medthority.com/medical-education/atopic-derm/guidelines-for-atopic-dermatitis/2025-12-16T13:47:53+00:00weekly0.7https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/ovarian-cancer/2025-12-05T09:46:08+00:00weekly0.7https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/parpi-selection-in-ovarian-cancer/2025-12-05T09:47:03+00:00weekly0.7https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/managing-ovarian-cancer-patients-on-parpi/2025-12-05T09:48:33+00:00weekly0.7https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/congress-highlights/2025-12-05T09:51:10+00:00weekly0.7https://www.medthority.com/medical-education/lupus-learning-zone/lupus-disease-awareness/2025-12-15T09:28:45+00:00weekly0.7https://www.medthority.com/medical-education/lupus-learning-zone/lupus-management/2025-12-15T09:29:09+00:00weekly0.7https://www.medthority.com/medical-education/lupus-learning-zone/long-term-organ-damage/2025-12-15T09:34:13+00:00weekly0.7https://www.medthority.com/medical-education/cardiovascular-metabolism-learning-zone/webinar-type-2-diabetes-and-hypertension-guidelines-practicalities-and-pitfalls-to-avoid/2026-01-13T09:16:19+00:00weekly0.7https://www.medthority.com/medical-education/cardiovascular-metabolism-learning-zone/hypertension/2026-01-13T09:03:31+00:00weekly0.7https://www.medthority.com/medical-education/cardiovascular-metabolism-learning-zone/type-2-diabetes/2026-01-13T09:06:52+00:00weekly0.7https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/expert-opinion/2026-01-16T10:08:55+00:00weekly0.7https://www.medthority.com/medical-education/food-allergy/publication-digests/2026-01-26T10:52:36+00:00weekly0.7https://www.medthority.com/medical-education/sabcs-2021-highlights/symposium-overview/2025-10-16T11:11:04+00:00weekly0.7https://www.medthority.com/medical-education/sabcs-2021-highlights/symposium-overview-her2-update-and-advances-with-tkis/2025-10-13T09:33:30+00:00weekly0.7https://www.medthority.com/medical-education/sabcs-2021-highlights/brain-metastases-managing-lmdtargeting-her2/2025-10-13T09:32:59+00:00weekly0.7https://www.medthority.com/medical-education/sabcs-2021-highlights/her2-breast-cancer-update/2025-10-13T09:33:15+00:00weekly0.7https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/high-efficacy-therapies-in-ms/2025-12-08T08:56:01+00:00weekly0.7https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/antiplatelet-therapy-in-acs/2026-01-27T11:52:23+00:00weekly0.7https://www.medthority.com/medical-education/osteoarthritis-associated-pain/burden-of-oa-associated-pain/2026-01-20T11:19:31+00:00weekly0.7https://www.medthority.com/medical-education/osteoarthritis-associated-pain/personalised-pain-management/2026-01-20T11:20:15+00:00weekly0.7https://www.medthority.com/medical-education/osteoarthritis-associated-pain/clinical-guidelines/2026-01-20T11:20:51+00:00weekly0.7https://www.medthority.com/medical-education/osteoarthritis-associated-pain/emerging-therapies/2025-12-11T15:13:01+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-learning-zone/disease-awareness/2025-12-09T14:39:58+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-learning-zone/diagnosis/2025-12-09T14:54:57+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-learning-zone/treatment/2025-12-09T14:58:16+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-learning-zone/guidelines/2025-12-09T15:00:51+00:00weekly0.7https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/disease-awareness/2025-12-15T09:46:05+00:00weekly0.7https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/treatment/2025-12-15T09:46:23+00:00weekly0.7https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/expert-opinion/2025-12-15T09:46:44+00:00weekly0.7https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/overview/2026-01-13T11:21:19+00:00weekly0.7https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/resources/2026-01-13T13:47:47+00:00weekly0.7https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/hydroxyethyl-starch---a-debate/2026-01-13T13:45:32+00:00weekly0.7https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/clinical-practice/2026-01-19T10:36:24+00:00weekly0.7https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/efficacy-and-safety/2026-01-19T10:40:03+00:00weekly0.7https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/practical-advice/2026-01-19T10:46:28+00:00weekly0.7https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/decision-making/2026-01-19T10:51:00+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-learning-zone/comorbidities/2025-12-09T14:56:15+00:00weekly0.7https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/publication-digests/2026-01-13T11:20:43+00:00weekly0.7https://www.medthority.com/medical-education/psoriasis-learning-zone/expert-insights/2025-12-09T15:03:18+00:00weekly0.7https://www.medthority.com/medical-education/managing-high-risk-nmibc/2026-03-03T10:35:25+00:00weekly0.8https://www.medthority.com/medical-education/alpha-1-antitrypsin-deficiency-bridging-care/2026-03-02T12:35:22+00:00weekly0.8https://www.medthority.com/medical-education/cidp-learning-zone/2025-12-16T15:57:39+00:00weekly0.8https://www.medthority.com/medical-education/hrr-mutation-testing-in-metastatic-prostate-cancer/2026-03-17T14:52:46+00:00weekly0.8https://www.medthority.com/medical-education/improving-outcomes-in-al-amyloidosis/2026-02-16T13:00:25+00:00weekly0.8https://www.medthority.com/medical-education/chronic-spontaneous-urticaria/2026-01-12T14:50:01+00:00weekly0.8https://www.medthority.com/medical-education/accredited-symposium-elevating-lopd-care/2026-02-26T16:15:51+00:00weekly0.8https://www.medthority.com/medical-education/ifn-gamma-in-hyperinflammation/2025-12-18T15:56:08+00:00weekly0.8https://www.medthority.com/medical-education/accredited-whats-new-in-tk2d2/2026-01-26T11:03:28+00:00weekly0.8https://www.medthority.com/medical-education/eano-2025-nf1-expert-insights/2025-12-18T15:04:39+00:00weekly0.8https://www.medthority.com/medical-education/eano-2025-evolving-care-in-nf1-pn/2025-11-06T09:11:45+00:00weekly0.8https://www.medthority.com/medical-education/esmo-congress-2025/2025-11-28T10:59:32+00:00weekly0.8https://www.medthority.com/medical-education/desmoid-tumors-insights-from-dgho-2025/2025-11-18T14:47:15+00:00weekly0.8https://www.medthority.com/medical-education/webinar-aa-in-skin-of-color-populations/2026-03-16T11:36:24+00:00weekly0.8https://www.medthority.com/medical-education/webinar-accredited-aa-in-skin-of-color-populations/2026-03-19T08:59:11+00:00weekly0.8https://www.medthority.com/medical-education/asco-gu-symposium-2026/2026-02-27T16:23:54+00:00weekly0.8https://www.medthority.com/medical-education/antiplatelet-therapy-in-acs-choices-and-controversies/2026-03-03T11:45:11+00:00weekly0.8https://www.medthority.com/medical-education/cardiovascular-metabolism-learning-zone/2026-01-13T09:02:46+00:00weekly0.8https://www.medthority.com/medical-education/parp-inhibitor-in-ovarian-cancer/2025-12-05T09:45:09+00:00weekly0.8https://www.medthority.com/medical-education/atopic-derm/2026-01-15T12:47:50+00:00weekly0.8https://www.medthority.com/medical-education/food-allergy/2025-12-18T15:07:40+00:00weekly0.8https://www.medthority.com/medical-education/multiple-sclerosis-ms-learning-zone/2025-12-08T08:38:54+00:00weekly0.8https://www.medthority.com/medical-education/hidradenitis-suppurativa-learning-zone/2026-01-14T08:18:03+00:00weekly0.8https://www.medthority.com/medical-education/molecular-diagnostics-for-ret-inhibition/2025-12-11T11:03:29+00:00weekly0.8https://www.medthority.com/medical-education/chronic-kidney-disease-learning-zone/2026-01-16T09:36:37+00:00weekly0.8https://www.medthority.com/medical-education/respiratory-syncytial-virus/2025-12-02T14:33:42+00:00weekly0.8https://www.medthority.com/medical-education/dna-repair-in-prostate-cancer-learning-zone/2026-03-03T15:40:05+00:00weekly0.8https://www.medthority.com/medical-education/improving-treatment-options-childhood-psoriasis/2026-01-13T08:29:46+00:00weekly0.8https://www.medthority.com/medical-education/very-brief-advice-for-tobacco-dependency-learning-zone/2025-12-02T14:04:34+00:00weekly0.8https://www.medthority.com/medical-education/cdk46-inhibitor-selection-in-metastatic-breast-cancer/2026-01-13T09:26:48+00:00weekly0.8https://www.medthority.com/medical-education/cancer-associated-thrombosis-learning-zone/2026-02-02T16:17:35+00:00weekly0.8https://www.medthority.com/medical-education/lupus-learning-zone/2025-12-15T09:25:28+00:00weekly0.8https://www.medthority.com/medical-education/major-depressive-disorder-treatment-resistant-depression/2025-12-11T10:51:14+00:00weekly0.8https://www.medthority.com/medical-education/glaucoma-learning-zone/2025-12-05T09:38:50+00:00weekly0.8https://www.medthority.com/medical-education/hiv-podcast-series/2025-09-12T14:56:33+00:00weekly0.8https://www.medthority.com/medical-education/supportive-care-in-oncology/2026-01-19T13:41:22+00:00weekly0.8https://www.medthority.com/medical-education/lipid-management-in-ascvd/2026-01-15T09:29:21+00:00weekly0.8https://www.medthority.com/medical-education/biosimilars-in-retinal-disease/2026-03-03T11:42:21+00:00weekly0.8https://www.medthority.com/medical-education/pompe-disease-key-findings-from-wms-2022/2026-01-27T15:19:39+00:00weekly0.8https://www.medthority.com/medical-education/alopecia-areata-learning-zone/2026-01-09T10:15:03+00:00weekly0.8https://www.medthority.com/medical-education/weight-control-in-diabetes/2025-12-02T13:12:29+00:00weekly0.8https://www.medthority.com/medical-education/complement-mediated-kidney-diseases-learning-zone/2026-01-16T10:17:31+00:00weekly0.8https://www.medthority.com/medical-education/responding-to-unmet-needs-for-metastatic-castration-resistant-prostate-cancer/2026-03-17T14:56:26+00:00weekly0.8https://www.medthority.com/medical-education/future-breast-cancer-2024/2025-10-16T11:09:02+00:00weekly0.8https://www.medthority.com/medical-education/advances-in-lymphoma-learning-zone/2026-03-12T12:23:41+00:00weekly0.8https://www.medthority.com/medical-education/roundtable-discussion-biologics-in-plaque-psoriasis/2025-09-12T14:56:35+00:00weekly0.8https://www.medthority.com/medical-education/think-thrombosis/2025-12-19T09:28:33+00:00weekly0.8https://www.medthority.com/medical-education/advances-in-hidradenitis-suppurativa/2026-01-26T12:54:29+00:00weekly0.8https://www.medthority.com/medical-education/management-of-adrenocortical-carcinoma-acc-webinar/2025-10-16T10:55:03+00:00weekly0.8https://www.medthority.com/medical-education/anti-cgrps-therapies-for-migraine/2025-12-15T11:38:36+00:00weekly0.8https://www.medthority.com/medical-education/growth-hormone-deficiency-learning-zone/2026-03-12T11:02:16+00:00weekly0.8https://www.medthority.com/medical-education/psoriasis-academy/2025-12-09T09:24:16+00:00weekly0.8https://www.medthority.com/medical-education/ulcerative-colitis/2025-12-02T14:18:34+00:00weekly0.8https://www.medthority.com/medical-education/myasthenia-gravis-learning-zone/2026-03-06T15:50:36+00:00weekly0.8https://www.medthority.com/medical-education/breast-cancer-2023/2025-10-13T10:18:05+00:00weekly0.8https://www.medthority.com/medical-education/lead-from-the-frontline-optimizing-first-line-treatment-selection-in-ph-all/2025-12-09T13:48:27+00:00weekly0.8https://www.medthority.com/medical-education/modern-management-rrmm/2025-12-09T14:13:04+00:00weekly0.8https://www.medthority.com/medical-education/Fluid-Management-Learning-Zone/2026-01-13T11:21:02+00:00weekly0.8https://www.medthority.com/medical-education/idiopathic-pulmonary-fibrosis-learning-zone/2025-12-15T09:44:23+00:00weekly0.8https://www.medthority.com/medical-education/psoriasis-learning-zone/2025-12-09T14:37:41+00:00weekly0.8https://www.medthority.com/medical-education/anti-tnf-treatment-using-biosimilars/2026-01-19T10:30:23+00:00weekly0.8https://www.medthority.com/medical-education/osteoarthritis-associated-pain/2025-12-11T15:11:08+00:00weekly0.8https://www.medthority.com/medical-education/2025-10-17T12:37:52+00:00weekly0.9